EP2654743A1 - Combination comprising d-apartic acid and l-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile and alzheimer's disease - Google Patents
Combination comprising d-apartic acid and l-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile and alzheimer's diseaseInfo
- Publication number
- EP2654743A1 EP2654743A1 EP11820851.1A EP11820851A EP2654743A1 EP 2654743 A1 EP2654743 A1 EP 2654743A1 EP 11820851 A EP11820851 A EP 11820851A EP 2654743 A1 EP2654743 A1 EP 2654743A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- aspartic acid
- arginine
- salts
- memory
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 230000015654 memory Effects 0.000 title claims abstract description 116
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 title claims abstract description 99
- 208000024827 Alzheimer disease Diseases 0.000 title claims abstract description 45
- 150000003839 salts Chemical class 0.000 title claims abstract description 43
- 206010012289 Dementia Diseases 0.000 title claims abstract description 33
- 230000006872 improvement Effects 0.000 title claims abstract description 18
- 230000001149 cognitive effect Effects 0.000 title claims description 26
- 239000002253 acid Substances 0.000 title claims description 14
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims abstract description 379
- 229930064664 L-arginine Natural products 0.000 claims abstract description 87
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 87
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims abstract description 85
- 229960005261 aspartic acid Drugs 0.000 claims abstract description 85
- 229940024606 amino acid Drugs 0.000 claims description 77
- 235000001014 amino acid Nutrition 0.000 claims description 77
- 150000001413 amino acids Chemical class 0.000 claims description 77
- 238000011282 treatment Methods 0.000 claims description 42
- 239000000203 mixture Substances 0.000 claims description 35
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 27
- 239000000126 substance Substances 0.000 claims description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 229960002989 glutamic acid Drugs 0.000 claims description 11
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 9
- 229940088594 vitamin Drugs 0.000 claims description 9
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 239000011782 vitamin Substances 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 7
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 6
- 239000011575 calcium Chemical class 0.000 claims description 6
- 229910052791 calcium Inorganic materials 0.000 claims description 6
- 239000011777 magnesium Chemical class 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 239000011734 sodium Substances 0.000 claims description 6
- 229910052708 sodium Inorganic materials 0.000 claims description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical class [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical class C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical class [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 5
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 5
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical class [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 5
- LXNHXLLTXMVWPM-UHFFFAOYSA-N Vitamin B6 Natural products CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 5
- 239000011591 potassium Chemical class 0.000 claims description 5
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 5
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 4
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 claims description 4
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 claims description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 claims description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical class [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 claims description 4
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical class [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 4
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims description 4
- AGBQKNBQESQNJD-UHFFFAOYSA-N lipoic acid Chemical compound OC(=O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 claims description 4
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 4
- 229960003512 nicotinic acid Drugs 0.000 claims description 4
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 4
- 239000011669 selenium Chemical class 0.000 claims description 4
- 229910052711 selenium Inorganic materials 0.000 claims description 4
- 235000019160 vitamin B3 Nutrition 0.000 claims description 4
- 239000011708 vitamin B3 Substances 0.000 claims description 4
- 239000011701 zinc Chemical class 0.000 claims description 4
- 229910052725 zinc Inorganic materials 0.000 claims description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical class [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 3
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 claims description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims description 3
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 3
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 3
- 229930003427 Vitamin E Natural products 0.000 claims description 3
- 229960003767 alanine Drugs 0.000 claims description 3
- 229910052802 copper Inorganic materials 0.000 claims description 3
- 239000010949 copper Chemical class 0.000 claims description 3
- 235000019152 folic acid Nutrition 0.000 claims description 3
- 229960000304 folic acid Drugs 0.000 claims description 3
- 239000011724 folic acid Substances 0.000 claims description 3
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 3
- 229960003987 melatonin Drugs 0.000 claims description 3
- 229960002477 riboflavin Drugs 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- 235000019159 vitamin B9 Nutrition 0.000 claims description 3
- 239000011727 vitamin B9 Substances 0.000 claims description 3
- 235000019165 vitamin E Nutrition 0.000 claims description 3
- 239000011709 vitamin E Substances 0.000 claims description 3
- 229940046009 vitamin E Drugs 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 claims description 2
- PHIQHXFUZVPYII-LURJTMIESA-N (S)-carnitine Chemical compound C[N+](C)(C)C[C@@H](O)CC([O-])=O PHIQHXFUZVPYII-LURJTMIESA-N 0.000 claims description 2
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 claims description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 2
- QRYRORQUOLYVBU-VBKZILBWSA-N Carnosic acid Natural products CC([C@@H]1CC2)(C)CCC[C@]1(C(O)=O)C1=C2C=C(C(C)C)C(O)=C1O QRYRORQUOLYVBU-VBKZILBWSA-N 0.000 claims description 2
- 108010087806 Carnosine Proteins 0.000 claims description 2
- ODKSFYDXXFIFQN-SCSAIBSYSA-N D-arginine Chemical compound OC(=O)[C@H](N)CCCNC(N)=N ODKSFYDXXFIFQN-SCSAIBSYSA-N 0.000 claims description 2
- 229930028154 D-arginine Natural products 0.000 claims description 2
- AFSDNFLWKVMVRB-UHFFFAOYSA-N Ellagic acid Chemical compound OC1=C(O)C(OC2=O)=C3C4=C2C=C(O)C(O)=C4OC(=O)C3=C1 AFSDNFLWKVMVRB-UHFFFAOYSA-N 0.000 claims description 2
- ATJXMQHAMYVHRX-CPCISQLKSA-N Ellagic acid Natural products OC1=C(O)[C@H]2OC(=O)c3cc(O)c(O)c4OC(=O)C(=C1)[C@H]2c34 ATJXMQHAMYVHRX-CPCISQLKSA-N 0.000 claims description 2
- 229920002079 Ellagic acid Polymers 0.000 claims description 2
- 108010024636 Glutathione Proteins 0.000 claims description 2
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 claims description 2
- 239000004158 L-cystine Substances 0.000 claims description 2
- 235000019393 L-cystine Nutrition 0.000 claims description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 2
- 229930182816 L-glutamine Natural products 0.000 claims description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 2
- 229930182844 L-isoleucine Natural products 0.000 claims description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 2
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 claims description 2
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 claims description 2
- CQOVPNPJLQNMDC-UHFFFAOYSA-N N-beta-alanyl-L-histidine Natural products NCCC(=O)NC(C(O)=O)CC1=CN=CN1 CQOVPNPJLQNMDC-UHFFFAOYSA-N 0.000 claims description 2
- RDHQFKQIGNGIED-MRVPVSSYSA-N O-acetyl-L-carnitine Chemical compound CC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C RDHQFKQIGNGIED-MRVPVSSYSA-N 0.000 claims description 2
- UFAHZIUFPNSHSL-MRVPVSSYSA-N O-propanoyl-L-carnitine Chemical compound CCC(=O)O[C@H](CC([O-])=O)C[N+](C)(C)C UFAHZIUFPNSHSL-MRVPVSSYSA-N 0.000 claims description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 2
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 2
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 claims description 2
- 229930003451 Vitamin B1 Natural products 0.000 claims description 2
- 229930003779 Vitamin B12 Natural products 0.000 claims description 2
- 229930003471 Vitamin B2 Natural products 0.000 claims description 2
- 229930003537 Vitamin B3 Natural products 0.000 claims description 2
- 229930003571 Vitamin B5 Natural products 0.000 claims description 2
- 229930003761 Vitamin B9 Natural products 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 229930003448 Vitamin K Natural products 0.000 claims description 2
- 229960001009 acetylcarnitine Drugs 0.000 claims description 2
- 230000002378 acidificating effect Effects 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 229960005070 ascorbic acid Drugs 0.000 claims description 2
- 235000010323 ascorbic acid Nutrition 0.000 claims description 2
- 239000011668 ascorbic acid Substances 0.000 claims description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 claims description 2
- 229960002079 calcium pantothenate Drugs 0.000 claims description 2
- CQOVPNPJLQNMDC-ZETCQYMHSA-N carnosine Chemical compound [NH3+]CCC(=O)N[C@H](C([O-])=O)CC1=CNC=N1 CQOVPNPJLQNMDC-ZETCQYMHSA-N 0.000 claims description 2
- 229940044199 carnosine Drugs 0.000 claims description 2
- 150000001805 chlorine compounds Chemical class 0.000 claims description 2
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 229960003067 cystine Drugs 0.000 claims description 2
- 229960002852 ellagic acid Drugs 0.000 claims description 2
- 235000004132 ellagic acid Nutrition 0.000 claims description 2
- 150000004673 fluoride salts Chemical class 0.000 claims description 2
- 229960003180 glutathione Drugs 0.000 claims description 2
- 235000003969 glutathione Nutrition 0.000 claims description 2
- 239000011630 iodine Substances 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 229960000310 isoleucine Drugs 0.000 claims description 2
- 235000019136 lipoic acid Nutrition 0.000 claims description 2
- 235000012661 lycopene Nutrition 0.000 claims description 2
- 229960004999 lycopene Drugs 0.000 claims description 2
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 claims description 2
- 239000001751 lycopene Substances 0.000 claims description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical class [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 claims description 2
- 229910044991 metal oxide Inorganic materials 0.000 claims description 2
- 150000004706 metal oxides Chemical class 0.000 claims description 2
- FAARLWTXUUQFSN-UHFFFAOYSA-N methylellagic acid Natural products O1C(=O)C2=CC(O)=C(O)C3=C2C2=C1C(OC)=C(O)C=C2C(=O)O3 FAARLWTXUUQFSN-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 claims description 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 2
- 229960001153 serine Drugs 0.000 claims description 2
- 150000003467 sulfuric acid derivatives Chemical class 0.000 claims description 2
- 229940026510 theanine Drugs 0.000 claims description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 2
- 229960002663 thioctic acid Drugs 0.000 claims description 2
- 125000002640 tocopherol group Chemical class 0.000 claims description 2
- 235000019149 tocopherols Nutrition 0.000 claims description 2
- 229930003802 tocotrienol Natural products 0.000 claims description 2
- 239000011731 tocotrienol Substances 0.000 claims description 2
- 229940068778 tocotrienols Drugs 0.000 claims description 2
- 235000019148 tocotrienols Nutrition 0.000 claims description 2
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 claims description 2
- 229960004441 tyrosine Drugs 0.000 claims description 2
- 235000019155 vitamin A Nutrition 0.000 claims description 2
- 239000011719 vitamin A Substances 0.000 claims description 2
- 235000010374 vitamin B1 Nutrition 0.000 claims description 2
- 239000011691 vitamin B1 Substances 0.000 claims description 2
- 235000019163 vitamin B12 Nutrition 0.000 claims description 2
- 239000011715 vitamin B12 Substances 0.000 claims description 2
- 235000019164 vitamin B2 Nutrition 0.000 claims description 2
- 239000011716 vitamin B2 Substances 0.000 claims description 2
- 235000009492 vitamin B5 Nutrition 0.000 claims description 2
- 239000011675 vitamin B5 Substances 0.000 claims description 2
- 235000019158 vitamin B6 Nutrition 0.000 claims description 2
- 239000011726 vitamin B6 Substances 0.000 claims description 2
- 235000021468 vitamin B8 Nutrition 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 235000019168 vitamin K Nutrition 0.000 claims description 2
- 239000011712 vitamin K Substances 0.000 claims description 2
- 150000003721 vitamin K derivatives Chemical class 0.000 claims description 2
- 229940045997 vitamin a Drugs 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- 229940046010 vitamin k Drugs 0.000 claims description 2
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims 1
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 claims 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims 1
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 claims 1
- 229930182832 D-phenylalanine Natural products 0.000 claims 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 claims 1
- 239000004395 L-leucine Substances 0.000 claims 1
- 235000019454 L-leucine Nutrition 0.000 claims 1
- 229930195722 L-methionine Natural products 0.000 claims 1
- 229930003268 Vitamin C Natural products 0.000 claims 1
- 229940050411 fumarate Drugs 0.000 claims 1
- 229960002885 histidine Drugs 0.000 claims 1
- 150000002576 ketones Chemical class 0.000 claims 1
- 229960003136 leucine Drugs 0.000 claims 1
- 229910052751 metal Inorganic materials 0.000 claims 1
- 239000002184 metal Substances 0.000 claims 1
- 229960004452 methionine Drugs 0.000 claims 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 claims 1
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 1
- 229960004295 valine Drugs 0.000 claims 1
- 235000019154 vitamin C Nutrition 0.000 claims 1
- 239000011718 vitamin C Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 35
- 230000002792 vascular Effects 0.000 abstract description 2
- 230000019771 cognition Effects 0.000 abstract 1
- 241000700159 Rattus Species 0.000 description 168
- 210000004556 brain Anatomy 0.000 description 127
- 238000002474 experimental method Methods 0.000 description 76
- 238000011084 recovery Methods 0.000 description 65
- 230000013016 learning Effects 0.000 description 64
- 210000002504 synaptic vesicle Anatomy 0.000 description 53
- 238000000034 method Methods 0.000 description 33
- 229910001868 water Inorganic materials 0.000 description 27
- 241000282414 Homo sapiens Species 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 23
- 102000004169 proteins and genes Human genes 0.000 description 23
- 108090000623 proteins and genes Proteins 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 21
- 210000002569 neuron Anatomy 0.000 description 21
- 239000002858 neurotransmitter agent Substances 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- 238000012360 testing method Methods 0.000 description 15
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 13
- 229930006000 Sucrose Natural products 0.000 description 13
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 13
- 102000005962 receptors Human genes 0.000 description 13
- 108020003175 receptors Proteins 0.000 description 13
- 239000005720 sucrose Substances 0.000 description 13
- 102000004190 Enzymes Human genes 0.000 description 12
- 108090000790 Enzymes Proteins 0.000 description 12
- 229940088598 enzyme Drugs 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
- XMXOIHIZTOVVFB-YBBRRFGFSA-L disodium;(2r)-2-aminobutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](N)CC([O-])=O XMXOIHIZTOVVFB-YBBRRFGFSA-L 0.000 description 11
- 210000004379 membrane Anatomy 0.000 description 11
- 241000282412 Homo Species 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 210000003568 synaptosome Anatomy 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000008399 tap water Substances 0.000 description 9
- 235000020679 tap water Nutrition 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 210000005013 brain tissue Anatomy 0.000 description 8
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 7
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 7
- 108090001066 Racemases and epimerases Proteins 0.000 description 7
- 102000004879 Racemases and epimerases Human genes 0.000 description 7
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 7
- 229960004373 acetylcholine Drugs 0.000 description 7
- 238000004128 high performance liquid chromatography Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 208000000044 Amnesia Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 208000031091 Amnestic disease Diseases 0.000 description 5
- 206010003062 Apraxia Diseases 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 230000006986 amnesia Effects 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 230000002255 enzymatic effect Effects 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 230000008449 language Effects 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- 230000002285 radioactive effect Effects 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 208000006888 Agnosia Diseases 0.000 description 4
- 241001047040 Agnosia Species 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 208000037259 Amyloid Plaque Diseases 0.000 description 4
- 229930195714 L-glutamate Natural products 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 208000010877 cognitive disease Diseases 0.000 description 4
- 230000002354 daily effect Effects 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000036651 mood Effects 0.000 description 4
- 239000008188 pellet Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 3
- 201000002882 Agraphia Diseases 0.000 description 3
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 3
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000008499 blood brain barrier function Effects 0.000 description 3
- 210000001218 blood-brain barrier Anatomy 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- XMXOIHIZTOVVFB-JIZZDEOASA-L disodium;(2s)-2-aminobutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CC([O-])=O XMXOIHIZTOVVFB-JIZZDEOASA-L 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 238000007824 enzymatic assay Methods 0.000 description 3
- 238000007667 floating Methods 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 230000006993 memory improvement Effects 0.000 description 3
- 210000001640 nerve ending Anatomy 0.000 description 3
- 210000000653 nervous system Anatomy 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 230000001242 postsynaptic effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- 241001464363 Anomia Species 0.000 description 2
- 206010002942 Apathy Diseases 0.000 description 2
- 241000238366 Cephalopoda Species 0.000 description 2
- 102000003914 Cholinesterases Human genes 0.000 description 2
- 108090000322 Cholinesterases Proteins 0.000 description 2
- 208000028698 Cognitive impairment Diseases 0.000 description 2
- 108010070357 D-Aspartate Oxidase Proteins 0.000 description 2
- 102000005680 D-aspartate oxidase Human genes 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 244000194101 Ginkgo biloba Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 241000237852 Mollusca Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 241000238414 Octopus vulgaris Species 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229960004308 acetylcysteine Drugs 0.000 description 2
- 229940009098 aspartate Drugs 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 230000003925 brain function Effects 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000002932 cholinergic neuron Anatomy 0.000 description 2
- 229940048961 cholinesterase Drugs 0.000 description 2
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 210000001787 dendrite Anatomy 0.000 description 2
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- -1 e.g. Chemical class 0.000 description 2
- 238000001493 electron microscopy Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 description 2
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 230000000971 hippocampal effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229940124280 l-arginine Drugs 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 206010027175 memory impairment Diseases 0.000 description 2
- 208000027061 mild cognitive impairment Diseases 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 235000001968 nicotinic acid Nutrition 0.000 description 2
- 239000011664 nicotinic acid Substances 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000000902 placebo Substances 0.000 description 2
- 229940068196 placebo Drugs 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 230000006886 spatial memory Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 230000003956 synaptic plasticity Effects 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 108091005703 transmembrane proteins Proteins 0.000 description 2
- 102000035160 transmembrane proteins Human genes 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- HOZBSSWDEKVXNO-QNDGGIRCSA-N (2s)-2-aminobutanedioic acid;(2r)-2-aminobutanedioic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O.OC(=O)[C@H](N)CC(O)=O HOZBSSWDEKVXNO-QNDGGIRCSA-N 0.000 description 1
- UMPSXRYVXUPCOS-UHFFFAOYSA-N 2,3-dichlorophenol Chemical class OC1=CC=CC(Cl)=C1Cl UMPSXRYVXUPCOS-UHFFFAOYSA-N 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229940124810 Alzheimer's drug Drugs 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 230000007082 Aβ accumulation Effects 0.000 description 1
- 101000798396 Bacillus licheniformis Phenylalanine racemase [ATP hydrolyzing] Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 208000024806 Brain atrophy Diseases 0.000 description 1
- 241000252229 Carassius auratus Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 206010010219 Compulsions Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UWTATZPHSA-N D-Serine Chemical compound OC[C@@H](N)C(O)=O MTCFGRXMJLQNBG-UWTATZPHSA-N 0.000 description 1
- 229930195711 D-Serine Natural products 0.000 description 1
- 229930195713 D-glutamate Natural products 0.000 description 1
- WHUUTDBJXJRKMK-GSVOUGTGSA-N D-glutamic acid Chemical compound OC(=O)[C@H](N)CCC(O)=O WHUUTDBJXJRKMK-GSVOUGTGSA-N 0.000 description 1
- FFEARJCKVFRZRR-SCSAIBSYSA-N D-methionine Chemical compound CSCC[C@@H](N)C(O)=O FFEARJCKVFRZRR-SCSAIBSYSA-N 0.000 description 1
- ASNFTDCKZKHJSW-UHFFFAOYSA-N DL-Quisqualic acid Natural products OC(=O)C(N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-UHFFFAOYSA-N 0.000 description 1
- 206010012219 Deliria Diseases 0.000 description 1
- 206010072269 Egocentrism Diseases 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010015535 Euphoric mood Diseases 0.000 description 1
- 108700012941 GNRH1 Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 102000018899 Glutamate Receptors Human genes 0.000 description 1
- 108010027915 Glutamate Receptors Proteins 0.000 description 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 208000004547 Hallucinations Diseases 0.000 description 1
- 206010021639 Incontinence Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-M Kainate Chemical compound CC(=C)[C@H]1C[NH2+][C@H](C([O-])=O)[C@H]1CC([O-])=O VLSMHEGGTFMBBZ-OOZYFLPDSA-M 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 206010027940 Mood altered Diseases 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 229930192627 Naphthoquinone Natural products 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 206010034719 Personality change Diseases 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- ASNFTDCKZKHJSW-REOHCLBHSA-N Quisqualic acid Chemical compound OC(=O)[C@@H](N)CN1OC(=O)NC1=O ASNFTDCKZKHJSW-REOHCLBHSA-N 0.000 description 1
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 description 1
- 241001339782 Scapharca broughtonii Species 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 102000003929 Transaminases Human genes 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 229930003756 Vitamin B7 Natural products 0.000 description 1
- HNSUOMBUJRUZHJ-UEMBJLSASA-N [(2r)-3-carboxy-2-hydroxypropyl]-trimethylazanium;(e)-4-hydroxy-4-oxobut-2-enoate Chemical compound OC(=O)\C=C\C(O)=O.C[N+](C)(C)C[C@H](O)CC([O-])=O HNSUOMBUJRUZHJ-UEMBJLSASA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 201000007201 aphasia Diseases 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000006736 behavioral deficit Effects 0.000 description 1
- 231100000871 behavioral problem Toxicity 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000002439 beta secretase inhibitor Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000007177 brain activity Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 210000005056 cell body Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 230000003727 cerebral blood flow Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 102000038379 digestive enzymes Human genes 0.000 description 1
- 108091007734 digestive enzymes Proteins 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229960003530 donepezil Drugs 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229940037395 electrolytes Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 230000001073 episodic memory Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000005153 frontal cortex Anatomy 0.000 description 1
- 229960003980 galantamine Drugs 0.000 description 1
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 229940049906 glutamate Drugs 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- 210000004884 grey matter Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 210000002287 horizontal cell Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000004715 keto acids Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- LDDHMLJTFXJGPI-UHFFFAOYSA-N memantine hydrochloride Chemical compound Cl.C1C(C2)CC3(C)CC1(C)CC2(N)C3 LDDHMLJTFXJGPI-UHFFFAOYSA-N 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000007510 mood change Effects 0.000 description 1
- 150000002791 naphthoquinones Chemical class 0.000 description 1
- 229960002362 neostigmine Drugs 0.000 description 1
- LULNWZDBKTWDGK-UHFFFAOYSA-M neostigmine bromide Chemical compound [Br-].CN(C)C(=O)OC1=CC=CC([N+](C)(C)C)=C1 LULNWZDBKTWDGK-UHFFFAOYSA-M 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 210000002682 neurofibrillary tangle Anatomy 0.000 description 1
- 230000003961 neuronal insult Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000001428 peripheral nervous system Anatomy 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 210000003538 post-synaptic density Anatomy 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000002442 prefrontal cortex Anatomy 0.000 description 1
- 210000005215 presynaptic neuron Anatomy 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 235000008160 pyridoxine Nutrition 0.000 description 1
- 239000011677 pyridoxine Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960004136 rivastigmine Drugs 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000004895 subcellular structure Anatomy 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 235000019157 thiamine Nutrition 0.000 description 1
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- SWGJCIMEBVHMTA-UHFFFAOYSA-K trisodium;6-oxido-4-sulfo-5-[(4-sulfonatonaphthalen-1-yl)diazenyl]naphthalene-2-sulfonate Chemical compound [Na+].[Na+].[Na+].C1=CC=C2C(N=NC3=C4C(=CC(=CC4=CC=C3O)S([O-])(=O)=O)S([O-])(=O)=O)=CC=C(S([O-])(=O)=O)C2=C1 SWGJCIMEBVHMTA-UHFFFAOYSA-K 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000003966 vascular damage Effects 0.000 description 1
- 230000031836 visual learning Effects 0.000 description 1
- 235000011912 vitamin B7 Nutrition 0.000 description 1
- 239000011735 vitamin B7 Substances 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000004885 white matter Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Definitions
- the present invention refers to a combination comprising D-aspartic acid and L-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile as Alzheimer's disease.
- Dementia senile is a loss of brain function of degenerative origin due to a series of causes leading to vascular damage (vascular dementia) and to Alzheimer's disease. Most of the dementia causes are not avoidable. Usually dementia occurs with age. The main symptoms are problems with language, memory, perception, personality change, cognitive abilities, confusion on persons, places or times, motory problems, changes in personality; anxiety, decreased ability to take care of themselves; decreased level of interest in daily life activities; depression; irritability; egocentrism; incontinence, problems in eating.
- Alzheimer's disease was detected for the first time by the German scientist Alois Alzheimer at the beginning of the past century. It is due to the onset in the brain of amyloid plaques which surround and disrupt neurons, so that people suffering from this disease lose their memory and cognitive functions, do not recognize places where they are and also lose the knowledge of persons around them, including their family members.
- Alzheimer's patients become completely inactive and inefficient in self-management (they do not cure their own person, do not eat or wash and do not feel the excretory stimuli).
- the people affected by Alzheimer's disease represent approximately 3-5% of male and female population between 55 and 65 years of age with an in- crease of about 5-8% in people between 65- and 75 years of age and about 15-20% in people between 75 and 85 years of age.
- the course of the disease includes a first mild phase, then an intermediate stage and finally a severe stage.
- the disease is often antic- ipated by the so-called mild cognitive impairment (MCI), a slight decrease in performance in different cognitive (memory, orientation and verbal skills) together with progressive amnesia and other cognitive impairments.
- MCI mild cognitive impairment
- the memory impairment is primarily circumscribed to sporadic episodes in dai- ly life, or disorders of the so-called on-going memory (remember what you ate for lunch, what was done during the day) and of prospective memory (which concerns the organization of the near future such as remembering to go to an appointment).
- the deficit progressively increases, also the backward episodic memory (concerning the facts of one's own life or public events of the past) and the semantic memory (the foreground) are affected, while the procedural memory (which concerns the automatic execution of actions) is relatively spared until the late stages of the disease. Starting from the mild and intermediate stages, increasing difficulties in speech production may then occur, with inability in definition of people or objects names.
- ⁇ - ⁇ is a protein present on the neuronal plasmatic membrane and is partly located within the neuron membrane and partly outside the neuron (transmembrane protein).
- ⁇ -secretase and ⁇ - secretase the 42 amino acids peptide is released.
- the latter becomes insoluble over time and precipitates on neurons forming tangled plaques, i.e. the amyloid plaques, which enwrap and disrupt the active neurons (1).
- a strong reduction of acetylcholine - a neurotransmitter essential to the brain function - was also observed in the brain, thus reducing memory and any other intellectual faculty (2).
- ⁇ - ⁇ ⁇ -Amyloid Precursor Protein
- the a-secretase and ⁇ -secretase cleave a big size precursor protein (a transmembrane protein) called ⁇ -Amyloid Precursor Protein ( ⁇ - ⁇ ), thus generating a peptide fragment of 42 amino acids which is ⁇ -amyloid.
- ⁇ - ⁇ ⁇ -Amyloid Precursor Protein
- the ⁇ -amyloid once generated, becomes insoluble and settles as extracellular aggregates on neurons membranes, thus forming the amyloid plaques.
- Tau a protein called "Tau”, abnormally phosphorylated, accumulates in the so-called “neurofibrillary tangles” disrupting the cholinergic neurons of the cortical areas, subcortical and hippocampal areas.
- the hippocampus is a brain structure that plays a crucial role in learning and memory processes and conse- quently the disruption of neurons in these regions is believed to be the main cause of memory loss.
- Alzheimer's disease Decreased levels of acetylcholine have been observed in the brain affected by Alzheimer's disease, a chemical neurotransmitter in the central and peripheral nervous system.
- Inhibitors of cholinesterase as, for example, physostigmine, galanta- mine, rivastigmine and neostigmine are used in therapy to mitigate the loss of acetylcholine (3).
- these drugs have only a temporary effect in time.
- Another set of drugs are those that directly affect the glutamatergic system, as memantine and donepezil. These drugs have also a limited efficacy in the treatment period (4). Since the formation of amyloid plaques in the brain affected by Alzheimer's are accompanied by an inflammation in situ, drugs having an anti-inflammatory effect are often used. Finally, for the treatment of the Alzheimer's disease, Gingko biloba (an extract from roots of tropical plants) is also used, based on the hypothesis that extracts of this plant are able to improve cerebral blood flow (5) increasing the oxygen supply. A new approach for the treatment of the Alzheimer's disease is based on the use of ⁇ -secretase inhibitors. Some synthetic compounds have been proposed belonging to the group of dichlorophenol derivatives (6).
- dementia senile In addition to Alzheimer's disease, there are other kinds of dementia senile, which are all included in a clinical framework of vascular dementia, characterized by insufficient blood flow to the brain and therefore by a reduced intake of oxygen and nutrients.
- the most common form of de- mentia is atherosclerosis caused by brain stroke or by any cause of blood flow interruption.
- D-aspartic acid is a naturally occurring amino acid having the same chemical structure of L-aspartic acid (an amino acid naturally present in free form in animal tissues and is also a constituent of proteins), but a dif- ferent spatial configuration (Fig.1).
- the D-aspartic acid has been discovered for the first time in 1977 in the brain of the sea mollusc Octopus vulgaris (8) and was later found in the endocrine and nervous tissues of several animal species (9) including rat (10-13) and humans (14-15). High levels of D-aspartic acid are found in the nervous system of the embryo of mammals including the rat (12.13) and humans (15).
- D-aspartic acid is significantly reduced in brains of patients affected by Alzheimer's disease (brain tissue obtained post-mortem) compared to brains of persons not affected by Alzheimer's disease (25).
- D-aspartic acid concentration is 10.5 nmoles/g tissue and in the brain of healthy subjects is 22.4 nmoles/g tissue. Similar values are 1
- D- aspartic acid is an endogenous neurotransmitter in the rat and human brain neurons. It is specifically located in synaptic vesicles (neuronal structures containing chemical neurotransmitters) and is involved in learning and memory.
- D-Aspartic acid in humans is able to improve learning and memory for receptor activation of D-Aspartic present in the cerebral cortex and hippocampus that represent areas of the brain more involved in learning and memory. Therefore, D-Aspartic acid in humans is an aid to improving memory, for example, in cases of Alzheimer's disease and dementia senile.
- the author of the present invention has also conducted a study in rats to evaluate the effectiveness of the treatment of D-Aspartic acid, L-Aspartic acid and L-arginine alone or the combination consisting of D-Aspartic acid and L-Arginine or a combination consisting of D-Aspartic acid and L-Aspartic acid in appropriate molecular ratios, on the improvement of cognitive activities and memory of rats and to evaluate the efficacy of the compound formed by the combination D-Aspartic acid and L-Arginine on improvement of cognitive activities and memory in patients with dementia senile and Alzheimer's.
- the study was conducted on different experimental groups of rats and then on a group of demented patients.
- Rats were subjected to oral treatment of certain amino acids alone and in combinations with each other. After a period of 30 days of treatment, the rats were tested for using the Learning System for Water- Maze (R-Morris, 1984), worldwide recognized as a method suitable for the purpose. The results showed that D-aspartic acid or L-arginine or the combination of D-Aspartic acid and the L-Aspartic acid induce a good positive effect on increasing learning and memory in rats. Rats treated with these compounds improve memory by about 2-2.5 times compared with the control group.
- the invention also concerns a pharmaceutical composition
- a pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or their salts, as active ingredients, in combination with one or more exci- pients and/or pharmaceutically acceptable adjuvants, for use in the treatment for restoring of and/or improving cognitive activities and memory in short and long period.
- the combination and the pharmaceutical composition according to the present invention can be used both in the treatment of dementia such as dementia senile and Alzheimer's disease in order to restore and im- P T/IT2011/000411
- the invention also concerns the association consisting of a combination of L- aspartic acid and L-arginine or salts thereof for simultaneous, separate or sequential use in the treatment to restore and/or improve cognitive activities and memory in the short and long period, for example in the treatment of dementias such as dementia senile and Alzheimer's disease.
- the combination or pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may contain a percentage of D-Aspartic acid or L-arginine or L-aspartic acid or salts thereof, which varies from 0.1% to 99.9% compared to the total of said D-aspartic acid and L-arginine or said D-aspartic acid and L-aspartic acid or salts thereof.
- the combination or pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention, can be administered in one or more daily doses, each dose comprising from 0,1 g to 10 g of D- Aspartic acid, 0.1 g to 10 g of L-Arginine and/or 0.1 g to 10 g L-Aspartic acid or salts thereof.
- the combination or pharmaceutical composition comprising or con- sisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may further comprise one or more basic or acidic substances in suitable amounts to bring the pH to neutrality.
- the combination or pharmaceutical composition comprising or con- sisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may contain salts of D- Aspartic acid or L-Aspartic acid selected from the group consisting of salts of Sodium, Potassium, Calcium, Magnesium, Zinc, Selenium, Copper, Manganese, Iodine.
- the combination or pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may further comprise at least an amino acid selected from the group consisting of D- or L-glutammic acid; D- or L-asparagine; D- or L-glutamine; D- or L- serine; D- or L-alanine, D- or L-threonine; D- or L-hystidine, D-arginine; D- or L-cysteine; D- or L-cystine; D- or L-valine; D- or L-methionine; D- or L-tyrosine; D- or L-phenylalanine; D- or L-isoleucine; D- or L-leucine; D- or L-tryptophan; D- or L-carnitine; propionyl-L or D-carnitine; D- or L- acetam
- the combination or pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may further comprise a ketoacid, such as, e.g., for example, alpha-oxalacetic acid, alpha- ketoglutaric, etc, or a salt thereof.
- a ketoacid such as, e.g., for example, alpha-oxalacetic acid, alpha- ketoglutaric, etc, or a salt thereof.
- the combination or pharmaceutical composition of the invention may include at least one water-soluble and/or liposoluble vitamin.
- Vitamin B1 (thiamine)
- Vitamin B2 (riboflavin)
- Vitamin B3 or Vitamin PP (niacin or nicotinic acid) Vitamin B5 or Vitamin W (pantothenic acid)
- Vitamin B6 or Vitamin Y pyridoxine or pyridoxamine or pyridox- al
- Vitamin B9 Vitamin B9 or Vitamin M (folic acid)
- Vitamin B12 (cobalamin)
- Vitamin C (ascorbic acid)
- liposoluble vitamins the following may be mentioned:
- Vitamin A retinol and analogues
- Vitamin D ergocalcipherol D2 and colecalcipherol D3
- Vitamin E tocopherol
- Vitamin K (naphthoquinone and derivatives).
- the combination or pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may further comprise at least one antioxidant selected the group consisting of coenzyme Q-10, ascorbic acid, folic acid, alpha-lipoic acid, glutathione, inosidol, tocopherols, tocotrienols (Vitamin E), superoxide dismutase, lycopene, ellagic acid, melatonin.
- at least one antioxidant selected the group consisting of coenzyme Q-10, ascorbic acid, folic acid, alpha-lipoic acid, glutathione, inosidol, tocopherols, tocotrienols (Vitamin E), superoxide dismutase, lycopene, ellagic acid, melatonin.
- combination or pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may further comprise at least one metal ion selected from the group consisting of magnesium, zinc, selenium, sodium, potassium, calcium, in the form of chlorides, sulphates, fluorides, or in the form of metal oxides.
- Figure 1 shows the composition and the stereo-chemical configu- IT2011/000411
- D-Asp D-Aspartic acid
- L-Asp L-Aspartic acid
- Figure 2 shows the concentration of D-aspartic acid in various regions of brain with Alzheimer's disease and normal brain (control).
- the values of the figure refer to the concentration of D-Aspartic acid assessed in the total homogenate of the brain tissue.
- Figure 3 shows an example of separation of D-Aspartic acid and L-Aspartic acid from other amino acids by HPLC.
- the figure shows a typical chromatogram run by HPLC of a mixture of standard amino acids consisting of 20 pmoles of D-aspartic acid and 100 pmoles di L- Aspartic acid and other L-amino acids (L-Glu, L-Ser, L-His, L-Thr, Gly, L-Arg, L-Ala, L-Tyr, L-Val, L-Met, L-lle, L-Leu, L-Phe and L-Lys), deriva- tized with OPA-NAC (ortho-phthaldialdehyde-N-acetyl-L-Cysteine).
- D- Aspartic acid is separated from other amino acids and can be quantified on the basis of the peak area.
- Figure 4 shows synaptosomes and synaptic vesicles from human brain.
- the figure shows a typical example of synaptosomes and synaptic vesicles purified from human brain of a healthy person of 30 years.
- the synaptosomes (0.8-1.5 m in size) represent the peripheral ends of the neuron and are filled with synaptic vesicles (40-70 nm in size) con- taining the chemical neurotransmitters.
- Example 1 Study on the role of D-Aspartic acid and L-Aspartic acid in restoring memory in patients with Alzheimer's disease and dementia senile
- D-Aspartic acid and other amino acids in the human brain was carried out by modifying the method described in (27) as follows. 0.5 g of the human brain (Alzheimer's or normal) of the frontal region was homogenized in 0.2 M perchloric acid in a 1 :10 ratio, then centri- fuged at 13,000 rpm for 5 min.
- the run program was: 0-10% B in 10 min, then 10-100% B in 7 min, then 100% B in 5 min and 0% B in 1 min.
- D-Asp acid exits at an elution time of 5.5 min followed by L- Asp at 6.2 min and L-Glu at 8.0 min and then by other amino acids.
- As standard was used a mixture consisting of 0.1 mM D-aspartic acid and 0.2 mM of other amino acids instead of the sample.
- the same procedure was carried out to evaluate the concentration of D-Asp and other amino acids in the homogenate of the whole human brain with Alzheimer's and control and in the synaptic vesicles isolated from these brain tissues.
- the purpose of this experiment is to see if D-Aspartic acid is present as a neurotransmitter in the synaptic vesicles (subcellular particles of neuron endings of 40-60 nm in size) and if there is a difference in concentrations between Alzheimer's brain and control brain.
- synaptic vesicles subcellular particles of neuron endings of 40-60 nm in size
- concentrations between Alzheimer's brain and control brain.
- the isolation of synaptosomes was carried out, 0.8-1.5 pm circular biological structures which represent the terminal part of nerve endings (dendrites). They are obtained by homogenization of nerve tissue with a solution of iso-osmotic sucrose.
- the synaptosomes contain synaptic vesicles that are rich in chemical neurotransmitters such as acetylcholine, L-glutamic acid, L-Aspartic acid, serotonin, GABA, etc..
- the preparation of synaptosomes was performed as follows: 1 g of brain tissue was homogenized in 20 ml of 0.32 M sucrose in 0.05 M Tris-HCI, pH 7.5 with a potter homogenizer with a piston - glass walls gap of 15-20 A. The homogenate was then centrifuged at 1 ,000 g for 10 min and the supernatant was centri- fuged at 22,000 g for 20 min.
- the resulting precipitate was taken up in 4 ml of sucrose 0.32 M and layered on a sucrose gradient consisting of 20 ml of 1.2 M sucrose and 20 ml of 0.8 M sucrose and then centrifuged at 22,000 g for 2 hours.
- the synaptosomal fraction of the visible in the interface between the solution 1.2 M and 0.8 M sucrose was collected and diluted with an equal volume of physiological buffer (125 mM NaCI, 3 mM KCI, 1.2 mM MgS0 4 , 1.2 mM CaCI 2, 1.2 mM NaH 2 P0 4 , 22 mM glucose, 10 mM Na2HC0 3 pH 7.4) and centrifuged for 90 min at 22,000 g.
- the pellet was taken up in 400 ⁇ of 0.32 M sucrose, pH 7.4 and layered on a second gradient consisting of 5 ml of 1.2 M sucrose, 5 ml of sucrose 0.95 M sucrose and 5 ml of 0.75 M, respectively, and centrifuged at 22,000 g for 90 min.
- the synaptosomal fraction located in the interface between 0.95 M and 0.75 M sucrose was collected and diluted in 4 ml of physiological buffer and analyzed by electron microscopy.
- synaptic vesicles 3 ml of the suspension of synaptosomes were diluted with 30 ml of distilled H20 to break the synaptosomes by os- mosis (vesicles being too small will not break) and allowed to stir for 30 min. Then centrifugation at 22,000 g for 20 min was carried out and the pellet consisting of purified synaptic vesicles was taken up in 0.5 ml of
- the pellet of synaptic vesicles was homogenized with a double volume of 0.2 M perchloric acid (to disrupt the vesicles and recover the amino acids contained therein) and centrifuged for 5 min at 22,000 g. The supernatant was then analyzed by HPLC for the content of D-aspartic acid and other amino acids.
- Fig 4 shows an example of a preparation of synaptosomes and synaptic vesicles from normal human brain
- Table 1 shows the concentration of D-aspartic acid and other amino acids in the homogenate of the brain as a whole and synaptic vesicles obtained from the brains of Alzheimer's patients and healthy patients.
- the results of this experiment shows that D-Aspartic acid is present in the brain in very small amounts compared to other amino acids, but in synaptic vesicles it presents high concentrations in comparison with other amino acids present in the vesicles (Table 1).
- this fact means that D-aspartic acid which is found in the brain is all concentrated in the synaptic vesicles
- D-aspartic acid can be considered a new chemical neurotransmitter involved in learning and memory processes, because as is shown later, the assumption of an integration based on D-Aspartic acid improves memory in Alzheimer's patients (see below).
- Table 1 shows the concentration of D-aspartic acid (D-Asp), L- aspartic acid (L-Asp) and L-glutamic acid (L-Glu) in the frontal area of the brain of Alzheimer's and normal patients and within synaptic vesicles ob- tained by the same brains
- * indicates nmoles of D-Asp, L-Asp, L-Glu and total free amino acids contained in 1 g of homogenate of human brain (obtained from the University of Chiga organ bank). * * Indicates the percent ratio of the concentration of single amino acid in relation to total amino acids. *** indicates nmoles of amino acids relat to 1 mg of total protein (soluble and insoluble) of vesicles sample. ** * * Indicates the ratio of amino acids expressed as nmol / mg of proteins in the sam used among those contained in purified synaptic vesicles and those contained in the brain homogenate.
- D-Aspartic acid is synthesized in the brain by a D-Aspartate racemase, an enzyme found in some mollusks (28) which transforms L- aspartic in D-aspartic (EC 5.1.1.13), in this study it was investigated whether the isaid enzyme was present or not in the human brain and if there is any difference in enzyme activity between the human brain affected by Alzheimer's disease and human control brain.
- the enzymatic assay is based on the following reactions:
- Alzheimer's brain or control brain was homogenized (1 :5) in 0.02 M phosphate buffer pH 8.0. Then 500 ⁇ of supernatant were mixed with 100 ⁇ I of Na L-aspartate 1 M (sample) or 100 ⁇ of distilled H 2 0 (blank sample) and 10 ⁇ of purified D-aspartate oxidase from rabbit kidney (22) and incubated for 2 hours at 37°C. Then the test mixture was added with 50 ⁇ of perchloric acid 5 M, mixed and centrifuged at 13,000 rpm for 5 min.
- Table 2 shows the enzyme units obtained from 1 g of the brains of people suffering from Alzheimer's and from 1 g of the brains of healthy people (control). As it can seen the racemase enzymatic activity in the Alzheimer's brain is significantly reduced and this phenomenon is in agreement with the fact that in the Alzheimer's brain also the content of D- Asp acid is present at concentrations significantly lower than in controls.
- Table 2 shows the enzymatic activity of D-aspartate racemase (synthesis of D-Asp acid) in the brains of healthy persons and of patients suffering from Alzheimer's disease.
- the receptors for the chemical neurotransmitter in the nervous system are membrane proteins of the neuron postsynaptic, and constitute the essential elements to capture the input transmitted by the neurotransmitter and then turn them into physiological signals to the cell (visual signals, memory signals, etc.).
- the present study it was ascertained whether in the Alzheimer's brain receptors of Aspartic acid were present and if there is a difference of these receptors in Alzheimer's brains compared to control brains.
- affinity (binding) experiments were carried out using radioactive D-Aspartic (D-[ 3 H] aspartic acid) and in accordance with the procedures described in the literature (29), amended as follows: 0.5 g of brain tissue was homogenized 1 :10 in NaCI 0.9%. Centrifuged at 13,000 rpm for 10 min. the supernatant was removed and the precipitate was taken up with 10 ml of 0.9% NaCI. It was centrifuged as above and the washing operation was repeated for 4 more times.
- D-Aspartic D-[ 3 H] aspartic acid
- the final precipitate was taken up in 2 ml of NaCI 0.9% and the binding assay was carried out on the latter as follows: 100 ⁇ of membrane suspension were mixed with 100 ⁇ I of D-[ 3 H] aspartate (100 nM) and 300 ⁇ 0.05M of phosphate buffer pH 7.4. Then 5.0 pi of each amino acid to be tested at concentrations between 0 and 0.1 mM was added to the assay mixture and incubated for 60 min at 20°C under stirring. Then the sample was centrifuged for 5 min at 13,000 rpm, it was washed 2 more times in phosphate buffer 0.05 m pH 7.4 and then the precipitate was dissolved in 400 ⁇ of 0.1 M NaOH.
- the L- glutamic acid and L-Aspartic acid do not have a low affinity in displacing D-Aspartic-membranes bond, thereby indicating that the receptors to which D-Asp is linked are specific receptors for this amino acid. It worth noting that the lower the concentration of cold amino acid displacing the radioactive, the more binding affinity is present. NMDA and others, even at concentrations of 100 mM, are not able at all to move D-Aspartic radioactive binding. This would indicate that these amino acids have no capacity on the D-Asp receptors.
- Ki inhibition constant or affinity constant
- Table 3 shows the activity of D-aspartic acid receptors (displacement of specific bonds for D-[ 3 H] Asp by various amino acids and amino acids analogues on the postsynaptic membranes (PSMS) obtained from the brains of Alzheimer's patients and normal persons).
- PSMS postsynaptic membranes
- concentration of D-[ 3 H] Asp in the binding assay was 100 nM, and the amino acids or amino acids analogues were 0 to 100 ⁇ .
- the inhibition constant (Ki) indicates the amino acids concentration capable of displacing 50% of the binding ties.
- the values indicate the mean ⁇ SD obtained from 4 experiments, each carried out on plasma membranes from Alzheimer's or control brains. Values > 00 indicate that the amino acid tested for displacement was completely inactive.
- the amino acid affinity to membrane receptors is as stronger (specific) as is lower the amino acid concentration which displaced 50% of the bonds of (D-[ 3 H] Asp) to the membranes.
- the purpose of this experiment was to know whether D-Aspartic ac- id orally administered enters or not in the brain and if it is transported into synaptic vesicles in order to explicate its action as a neurotransmitter.
- the experiment was carried out on adult rats of the Wistar strain (kept in cages and in a suitable environment according to the ministerial regulations).
- the rats of the first group consisting of 5 animals, were given to drink a solution of 20 mM sodium D-aspartate.
- a second group of 5 rats was given to drink sodium L-aspartate at a concentration of 20 mM and finally the third group of 5 rats was given to drink tap water.
- the duration of treatment was 15 days.
- Table 4 shows the concentration of D-Aspartic acid in whole brain and in synaptic vesicles in rats after the intake of 20 mM D-Asp or 20 mM L-Asp or H 2 0.
- Rats which drunk tap water (control)
- the values represent the mean ⁇ SD obtained from 5 adult rats treated with 20 mM sodium D-aspartate or 20 mM sodium L-aspartate or tap water (control).
- * Indicates nmoles of D-Asp contained in 1 g of brain homoge- nate or nmoles referred to the content of 1 mg of the total proteins (soluble and insoluble).
- ** Indicates nmoles of D-Asp contained in synaptic vesicles prepared from 1 g of brain or the nmoles referred to 1 mg of total proteins (soluble and insoluble).
- Each patient was given orally a solution comprising 10 ml of sodium D-aspartate at a concentration of 2 M (2.66 g of D-Aspartic acid, corresponding to 3.12 g of sodium D-aspartate) mixed in half a glass of water or juice after lunch or dinner.
- the solution of sodium D-aspartate given to the patient consisted of a dietary supplement approved by the Ministry of Health and covered by a patent and marketed under the trademark DADAVIT ® and used as a supplement for other purposes.
- the experiment had a duration of 30 days and was carried out under medical control. After this period, some specific symptoms of the Alzheimer's disease (below) have been evaluated and compared with those of the same patients before therapy.
- Amnesia Patients with dementia due to Alzheimer's have good memory of past things but cannot remember recent essential things as, for example, they forget the place where they are, or they do not, for example, remember where is the toilet of their house, etc.
- Agnosia The inability to recognize common things e.g. fruit, pets, etc..
- Anomia Inability to name an object, while recognizing it.
- Disorientation in time and space Inability to remember the day or month or season or year, as well as inability to remember the place where he is.
- Agraphia The subject has difficulty in writing. In the most severe forms he cannot even write his own signature.
- rats were used as an animal model as they possess a biological system which is considered very similar to that of humans. So, it is believed that such biological effects induced in rats by a substance will be present also in humans.
- D-aspartate is meant the salt of D-aspartic acid.
- L-aspartate is meant the salt of L-aspartic acid.
- Rats were held 2-3 per cage, separated by sex, in an environment controlled for temperature (23- 24°C) and humidity (60%), with cycles of daylight and night.
- the hygienic conditions of housing were in line with international standards of mainten- 1 000411
- the Morris method Water Maze-1984 (R-Morris, 1984) has been used. It consists in the evaluation of learning activity and memory in rats in remembering the position of the floating and not visible platform in a tank water. This method is officially considered the most suitable, because the rat is subjected to a type of learning and memory that involves temporal and spatial memory.
- the rat after finishing the course of treatment with the substance the efficiency of memory of which is to be tested, is IMMERSO into a circular pool of 2 meters in diameter and 50 cm high, filled with water (made opaque wit an addition of milk) and containing a floating platform (10x10 cm) at the center of the tank below the surface of water.
- the rat swims randomly to seek support for salvation. After reaching the platform, the rat is left on the platform for about 30 seconds allowing it to store the spatial position of the platform in the tank. Then it is dried and put it in his cage. In the first attempts, the rat takes a long time to find the platform (1.5-2 min), then gradually learns the location of the platform and takes less time to find it. If the drug being tested has an activity on learning and memory, the rat will learn quicker the position of the platform compared to a control rat. In this case, the complete experiment lasted 5 days with 2 sessions per day: one in the morning and evening. For each exercise of Water-Maze time in seconds that the rat employed to reach the platform is relieved. Then, the data were statistically processed (using the test "ANOVA" one-way and two-way) to know the significance of the treatment effect of the compound versus placebo.
- the experiment was carried out as follows: 5 rats males and 5 rats females drank a solution of 20 mM D-aspartic acid (dissolved in 20 mM NaOH to pH 7.0) for 30 consecutive days. Throughout the treatment the rats were free to drink and eat (food for rats) without limitation. At the thir- 2011/000411
- each rat was subjected to the experiment of learning and memory with the "Water-Maze" by making 2 attempts per day (10 hours and at 17 hours). To this purpose it was used a circular pool of 2 meters in diameter and 50 cm in height containing water made opaque (by adding milk). At the center of the tank a floating platform was put at 1 cm below the water surface to avoid the rat from seeing. Every day for 5 consecutive days, each rat of the group was placed in the tank (in the same place) and left free to swim until it found the platform on which to lean. After finding the platform the rat was left for 20 sec on the platform allowing him to store the position of the platform. Then the rat was dried and put back in the cage. After each exercise the time that the rat had employed to reach the platform was collected. The Water-Maze experiment was carried out every day at 10 and 18.
- the rats drank a solution of 20 mM L-Aspartic acid for 30 days (see experimental part, section 1.7). Then the learning and memory experiment began using the Water-Maze system. This method consisted in placing the rat in a tank of 2 m in diameter with a central platform and containing opaque water and the time that the rats employed to reach the platform were collected. This experiment was carried out 2 times a day (at 10.00 and at 18.00) and for 5 consecutive days. Finally, the average and SD of 10 rats for each experiment was calculated and the significance of differences of time in seconds to reach the platform was calculated using the Student's T. A Student's T value, P ⁇ 0.05 was assumed statistically valid.
- the rats drank a solution of 20 mM L-Arginine for 30 days (see experimental part, section 1.7). Then the learning and memory experiment began using the Water-Maze system. This consisted in placing the rat in a tank of 2 m in diameter with a central platform and containing opaque water and the time that the rats employed to reach the platform. This experiment was carried out 2 times a day (at 10.00 and at 18.00) and for 5 consecutive days. Finally, the average and SD of 5 male and 5 female rats for each experiment was calculated. Finally, it has been calculated the average and SD of 10 rats for each experiment and the significance of differences of time in seconds to reach the platform was calculated using the Student's T.. A Student's T value, P ⁇ 0.05 was assumed statistically valid.
- D-Aspartic acid produces a good improvement in learning and memory in rats. Indeed, a comparison of the average time in seconds to reach the platform, and the value of P of Student'T, shows that up to the first attempt of the 4 th day of testing with Water-Maze system there were no significant improvements in learning and memory compared with rats in the control group (P value of Student'T is always greater than 0.05 , P> 0.05). However, the second attempt of 4 th day, it has been observed that the rats reached the platform with times statistically significant compared to the same day of the controls (see values from Table 9 compared to the values of Table 6). This value of such significant learning is also confirmed in the two sessions of Day 5 th where, for both sessions, the value P is always less than 0.001 (P ⁇ 0.001) (Table 9).
- the rats drank a solution of 20 mM D-Aspartic acid for 30 days (see experimental part, section 1.7). Then the learning and memory experiment began using the Water-Maze system. This consisted in placing the rat in a tank of 2 m in diameter with a central platform and containing opaque water; the time that rats employed to reach the platform has been measured. This experiment was carried out 2 times a day (at 10.00 and at 18.00) and for 5 consecutive days. Finally, it was calculated the mean and SD of 5 male and 5 female rats for each experiment. Finally, it has been calculated the average and SD of 10 rats for each experiment and the significance of differences of time in seconds to reach the platform was calculated using the Student's T.. A Student's T value, P ⁇ 0.05 was assumed statistically valid.
- the rats drank a solution of 20 mM D-Aspartic acid + 20 mM L-Aspartic acid for 30 days (see experimental part, section .7).
- the learning and memory experiment began using the Water-Maze system. This test consisted in placing the rat in a tank of 2 m in diameter with a central platform and containing opaque water; the time that rats employed to reach the platform has been measured. This experiment was carried out 2 times a day (at 10.00 and at 18.00) and for 5 consecutive days. Finally, was calculated the mean and SD of 5 male and 5 female rats for each experiment. Finally, it has been calculated the average and SD of 10 rats for each experiment and the significance of differences of time in seconds to reach the platform was calculated using the Student's T.. A Student's T value, P ⁇ 0.05 was assumed statistically valid.
- composition consisting of D-Aspartic acid, 20 mM and 10 mM L-arginine improves very significantly the learning and memory in rats and the efficiency of this compound is much higher even than the improvement induced by D Aspartic acid or by the compound including D- Aspartic acid or by L-Arginine or by L-Aspartic acid.
- Table 11 after the rats were treated with the compound consisting of D- Aspartic acid and L-Arginine, the rat has learned a lot before the other treatments the position of the platform.
- the rats drank a solution of 20 mM D-Aspartic acid + 10 mM L-Arginine for 30 days (see experimental part, section 1.7). Then the learning and memory experiment began using the Water-Maze system. The test consisted in placing the rat in a tank of 2 m in diameter with a central platform and containing opaque water; the time that rats employed to reach the platform has been measured. This experiment was carried out 2 times a day (at 10.00 and at 18.00) and for 5 consecutive days. Finally, the average and SD of 10 rats for each experiment it has been calculated and the significance of differences of times in seconds to reach the platform was calculated using the Student's T.. A Student's T value, P ⁇ 0.05 was assumed statistically valid
- composition consisting of 20 mM D-Aspartic acid and L- arginine 20 m ' M also very significantly improves learning and memory in rats with efficiency comparable to the composition consisting of D-Aspartic acid, 20 mM and 10 mM L-arginine (for the latter composition the times of the rats for reaching the platform are not reported in the table, because the P values of Student's T are in practice the same as those shown in Table 11).
- D-Aspartic acid or L-arginine or the combination of D-Aspartic acid with L-Aspartic acid induce a good positive effect on increasing learning and memory in rats. Rats treated with these compounds improve memory by about 2-2.5 times compared with the control group.
- EXAMPLE 3 Study on the effects of the treatment with D-Aspartic acid, L-Aspartic Acid, L-Arginine, with a combination consisting of D- Aspartic acid and L-Aspartic acid, and with a combination consisting of D- Aspartic Acid and L -arginine about their build up in the brain and in the synaptic vesicles
- D-Aspartic acid is usually present in the endogenous form in the brain and in synaptic vesicles of rats.
- concentration of D-aspartic acid is on average 35 ⁇ 5 nmoles / g of brain (4.65 ⁇ 0.66 pg / g).
- a substantial amount of D-Aspartic acid corresponding approximately to 10-15% of the total amount that is located in synaptic vesicles, i.e., in the cell structures that are rich in neurotransmitters and that are localized at the nerve endings of neurons (dendrites).
- Neurotransmitters are molecules that following nerve or electrical stimulus are transferred from pre-synaptic neuron to post-synaptic neuron creating cell information which are at the base of learning and memory processes. Normally in synaptic vesicles, the P T/IT2011/000411
- the concentration of amino acids in synaptic vesicles is expressed in terms of nmoles/mg of vesicular protein.
- the determination of amino acids was carried out using HPLC methods described in section 1.1.
- the preparation of synaptic vesicles from rat brain was performed as described in section 1.2.
- the results refer to the average ⁇ SD obtained from 5 adult males and 5 adult females.
- D-Aspartic acid in the form of sodium D-aspartate
- this amino acid accumulates significantly in the brain and synaptic vesicles and its concentration in these tissues increases the value of about 2.8 times compared to that in the brain and vesicles from con- trol rats.
- D-Aspartic acid ingested can pass the blood brain barrier, enter the neurons of the brain and move into synaptic vesicles where acts as a neurotransmitter chemical (Table 12).
- Table 12 By a comparative study of the maximum concentration of D-Aspartic synaptic acid in the brain and in vesicles occurs when the animal ingests the compound consisting of D-Aspartic acid and L-arginine, where the concentration may be as high as 120 nmol / g in whole brain and 585 nmol /mg protein in synaptic vesicles. Therefore, this result indicates that the combination of D-Aspartic acid and L-Arginine is the most efficient compound to introduce D-Aspartic acid in the brain and therefore also the compound that gives more brain activity and that validates the results obtained in experiments on memory above mentioned.
- ESEMPIO 4 Study on the effects of the treatment with D-Aspartic acid L- Aspartic Acid, L-Arginine, with an association consisting in D-Aspartic acid and L-Aspartic acid, and an association consisting in D-Aspartic Acid and L -arginine on the health of rats
- EXAMPLE 5 Study on the effects of an association consisting of D- Aspartic acid and L-Arginine to improve memory in patients with dementia senile and Alzheimer's disease.
- Each patient was given a daily dose consisting of 2.5 g of D- Aspartic acid, 1.5 g of L-arginine.
- the mixture of the two amino acids was added 1.1 g of sodium bicarbonate in order to dissolve D-Aspartic acid and L-arginine in water.
- the patient was given to drink a solution made as above dissolved in half a glass of spring water or juice, preferably with food (lunch or after dinner).
- the treatment lasted for 30 consecutive days. After this time, for each patient the cognitive activities and memory, before and after treatment, have been assessed.
- the improvement or restoration of memory was evaluated using the following clinical parameters: Amnesia, Apraxia, Agnosia, Anomy, disorientation in time and space, agraphia, mood changes, language problems and loss of initiatives.
- Table 13 Effect of an association of D-Aspartic acid and L-Arginine on cognitive activities and memory in dementia senile with a tendency to Alzheimer's
- Each patient took a daily dose consisting of 2.5 g of D-Aspartic acid and 1.5 g of L-Arginine and fed for 30 days.
- the assessment of recovery of cognitive activities and memory has been expressed in terms of arbitrary evaluating before and after treatment, giving a value of 100% and cognitive activities and memory of people without dementia and of the same age group.
- Rats were subjected to oral treatment of some amino acids alone and in association with each other. After a period of 30 days of treatment, the rats were tested by the Water-Maze Learning System, universally rec- ognized as a method suitable for this purpose. This study showed that, among the various combinations of amino acids tested, the mixture consisting of 20 mM D-aspartate acid and 10 mM L-arginine was found to be the most effective for the improvement of memory in rodents. In addition, the mixture consisting of 20 mM D-Aspartic acid and 20 mM L-arginine has efficiently responded for increasing memory.
- the human study consisted in giving a drinking dose per day including 2.5 g of D-Aspartic acid and 1.5 g of L-arginine dissolved in 1/2 glass of water for 30 consecutive days to a group of elder persons suffering from dementia senile with tendency to the Alzheimer's disease. The result showed that in all patients there was a recovery of 60-70% of memory.
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to a combination comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for the improvement of cognition activity and memory in dementia such as dementia senile of vascular origin or other origin and Alzheimer's disease.
Description
COMBINATION COMPRISING D-APARTIC ACID AND L-ARGININE OR SALTS THEREOF FOR THE IMPROVEMENT OF COGNITIVE ACTIVITIES AND MEMORY IN DEMENTIA SUCH AS DEMENTIA SENILE AND ALZHEIMER'S DISEASE
The present invention refers to a combination comprising D-aspartic acid and L-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile as Alzheimer's disease.
Dementia senile is a loss of brain function of degenerative origin due to a series of causes leading to vascular damage (vascular dementia) and to Alzheimer's disease. Most of the dementia causes are not avoidable. Usually dementia occurs with age. The main symptoms are problems with language, memory, perception, personality change, cognitive abilities, confusion on persons, places or times, motory problems, changes in personality; anxiety, decreased ability to take care of themselves; decreased level of interest in daily life activities; depression; irritability; egocentrism; incontinence, problems in eating.
Alzheimer's disease was detected for the first time by the German scientist Alois Alzheimer at the beginning of the past century. It is due to the onset in the brain of amyloid plaques which surround and disrupt neurons, so that people suffering from this disease lose their memory and cognitive functions, do not recognize places where they are and also lose the knowledge of persons around them, including their family members.
In the most advanced forms, the Alzheimer's patients become completely inactive and inefficient in self-management (they do not cure their own person, do not eat or wash and do not feel the excretory stimuli). The people affected by Alzheimer's disease represent approximately 3-5% of male and female population between 55 and 65 years of age with an in- crease of about 5-8% in people between 65- and 75 years of age and about 15-20% in people between 75 and 85 years of age.
The course of the disease includes a first mild phase, then an intermediate stage and finally a severe stage. The disease is often antic-
ipated by the so-called mild cognitive impairment (MCI), a slight decrease in performance in different cognitive (memory, orientation and verbal skills) together with progressive amnesia and other cognitive impairments. The memory impairment is primarily circumscribed to sporadic episodes in dai- ly life, or disorders of the so-called on-going memory (remember what you ate for lunch, what was done during the day) and of prospective memory (which concerns the organization of the near future such as remembering to go to an appointment). Then, the deficit progressively increases, also the backward episodic memory (concerning the facts of one's own life or public events of the past) and the semantic memory (the foreground) are affected, while the procedural memory (which concerns the automatic execution of actions) is relatively spared until the late stages of the disease. Starting from the mild and intermediate stages, increasing difficulties in speech production may then occur, with inability in definition of people or objects names.
In advanced stages, behavioral problems may occur (wandering, compulsion to repeat movements or actions, inconsistent behavioral reactions) or psychiatric problems (confusion, anxiety, depression and occasionally, deliria and hallucinations). As the disease progresses, people have not only memory impairment, but also a loss in instrumental functions mediated by the associative cortex, and may therefore present aphasia and apraxia.
From the epidemiological standpoint, apart from rare genetic familiar forms wherein the person is affected by the disease at a young age, the main factor related to the incidence of the disease is age. Typically, after age 65, the incidence of the disease increases progressively with age, reaching a significant spread in population over age 85. Biological and biochemical causes of the disease are due to a widespread disruption of neurons, caused mainly by a small protein (or polypeptide) of 42 amino acids, i.e., β-amyloid. Such peptide is originated from a membrane protein
P T/IT2011/000411
3
with molecular weight of about 90,000 Da, the β-Amyloid Precursor Protein (β-ΑΡΡ). β-ΑΡΡ is a protein present on the neuronal plasmatic membrane and is partly located within the neuron membrane and partly outside the neuron (transmembrane protein). When this protein is hydrolyzed in two specific points by the action of two enzymes, β-secretase and γ- secretase, the 42 amino acids peptide is released. The latter becomes insoluble over time and precipitates on neurons forming tangled plaques, i.e. the amyloid plaques, which enwrap and disrupt the active neurons (1). This results in a blockage of synaptic transmission and progressive brain atrophy. A strong reduction of acetylcholine - a neurotransmitter essential to the brain function - was also observed in the brain, thus reducing memory and any other intellectual faculty (2).
In healthy subjects the β-ΑΡΡ (β-Amyloid Precursor Protein) is degraded in situ by the action of two digestive enzymes. The a-secretase and β-secretase (a variant of a-secretase) enzymes cleave a big size precursor protein (a transmembrane protein) called β-Amyloid Precursor Protein (β-ΑΡΡ), thus generating a peptide fragment of 42 amino acids which is β-amyloid. The β-amyloid, once generated, becomes insoluble and settles as extracellular aggregates on neurons membranes, thus forming the amyloid plaques. These are cell clusters which over time disrupt the healthy neurons and also give rise to an inflammatory process that triggers an immune response by recalling macrophages and neutrophils with production of cytokines, interleukins which contribute to neuronal damage. Other studies have found that in people with Alzheimer's disease an addi- tional pathological mechanism occurs. Within the neurons, a protein called "Tau", abnormally phosphorylated, accumulates in the so-called "neurofibrillary tangles" disrupting the cholinergic neurons of the cortical areas, subcortical and hippocampal areas. The hippocampus is a brain structure that plays a crucial role in learning and memory processes and conse- quently the disruption of neurons in these regions is believed to be the
main cause of memory loss. There is no specific cure for Alzheimer's disease. Decreased levels of acetylcholine have been observed in the brain affected by Alzheimer's disease, a chemical neurotransmitter in the central and peripheral nervous system. Inhibitors of cholinesterase (the enzyme which catabolizes acetylcholine) as, for example, physostigmine, galanta- mine, rivastigmine and neostigmine are used in therapy to mitigate the loss of acetylcholine (3). However, we have to refer that these drugs have only a temporary effect in time. Another set of drugs are those that directly affect the glutamatergic system, as memantine and donepezil. These drugs have also a limited efficacy in the treatment period (4). Since the formation of amyloid plaques in the brain affected by Alzheimer's are accompanied by an inflammation in situ, drugs having an anti-inflammatory effect are often used. Finally, for the treatment of the Alzheimer's disease, Gingko biloba (an extract from roots of tropical plants) is also used, based on the hypothesis that extracts of this plant are able to improve cerebral blood flow (5) increasing the oxygen supply. A new approach for the treatment of the Alzheimer's disease is based on the use of β-secretase inhibitors. Some synthetic compounds have been proposed belonging to the group of dichlorophenol derivatives (6). However these compounds, though have produced encouraging results in laboratory animals, they have never been used on humans in the treatment for Alzheimer's disease because when administered orally they are unable to cross the blood brain barrier. Finally, a cure based on immunotherapy has been proposed using vaccines based on antibodies anti-Beta-amyloid. Also in this case the treatment was not successful because the antibody is not able to cross the blood brain barrier (7).
In addition to Alzheimer's disease, there are other kinds of dementia senile, which are all included in a clinical framework of vascular dementia, characterized by insufficient blood flow to the brain and therefore by a reduced intake of oxygen and nutrients. The most common form of de-
mentia is atherosclerosis caused by brain stroke or by any cause of blood flow interruption.
In view of the foregoing, there appears to be a clear need of providing new therapies for the treatment of dementia such as dementia senile and Alzheimer's disease which do not present the disadvantages of known therapies.
D-aspartic acid is a naturally occurring amino acid having the same chemical structure of L-aspartic acid (an amino acid naturally present in free form in animal tissues and is also a constituent of proteins), but a dif- ferent spatial configuration (Fig.1). The D-aspartic acid has been discovered for the first time in 1977 in the brain of the sea mollusc Octopus vulgaris (8) and was later found in the endocrine and nervous tissues of several animal species (9) including rat (10-13) and humans (14-15). High levels of D-aspartic acid are found in the nervous system of the embryo of mammals including the rat (12.13) and humans (15). On the other hand, in adults high levels of D-aspartic acid are found in the endocrine glands (16- 20). Recent studies about some marine molluscs have shown that D- aspartic acid is present in the retina and has a role in the visual system (21-22). Moreover, experiments on hippocampal slices of mice have shown that D-aspartic acid is involved in synaptic plasticity of neurons (23) and, finally, water maze experiments (an experimental method to assess the spatial learning of rats and mice) carried out on young rats have shown that there is a direct correlation between D-aspartic acid concentration in the brain and spatial memory (24). It is interesting to note that in humans, it has been shown that, the concentration of D-aspartic acid is significantly reduced in brains of patients affected by Alzheimer's disease (brain tissue obtained post-mortem) compared to brains of persons not affected by Alzheimer's disease (25). In the white matter of a brain with Alzheimer's, D-aspartic acid concentration is 10.5 nmoles/g tissue and in the brain of healthy subjects is 22.4 nmoles/g tissue. Similar values are
1
6
also found in gray matter (25). In addition, subsequent studies on the brains of people suffering from Alzheimer's disease and healthy brains, have shown that also in other regions of the brain (frontal cortex, hypothalamus, hippocampus, occipital and parietal cortex, cerebellum, etc.) the concentration of D-aspartic acid in Alzheimer's was found significantly reduced compared to that found in corresponding areas of healthy brains (26) (Fig. 2).
The author of the present invention has recently discovered that D- aspartic acid is an endogenous neurotransmitter in the rat and human brain neurons. It is specifically located in synaptic vesicles (neuronal structures containing chemical neurotransmitters) and is involved in learning and memory.
Studies carried out show that D-Aspartic acid in humans is able to improve learning and memory for receptor activation of D-Aspartic present in the cerebral cortex and hippocampus that represent areas of the brain more involved in learning and memory. Therefore, D-Aspartic acid in humans is an aid to improving memory, for example, in cases of Alzheimer's disease and dementia senile. The author of the present invention has also conducted a study in rats to evaluate the effectiveness of the treatment of D-Aspartic acid, L-Aspartic acid and L-arginine alone or the combination consisting of D-Aspartic acid and L-Arginine or a combination consisting of D-Aspartic acid and L-Aspartic acid in appropriate molecular ratios, on the improvement of cognitive activities and memory of rats and to evaluate the efficacy of the compound formed by the combination D-Aspartic acid and L-Arginine on improvement of cognitive activities and memory in patients with dementia senile and Alzheimer's. First, The study was conducted on different experimental groups of rats and then on a group of demented patients. Rats were subjected to oral treatment of certain amino acids alone and in combinations with each other. After a period of 30 days of treatment, the rats were tested for using the Learning System for Water-
Maze (R-Morris, 1984), worldwide recognized as a method suitable for the purpose. The results showed that D-aspartic acid or L-arginine or the combination of D-Aspartic acid and the L-Aspartic acid induce a good positive effect on increasing learning and memory in rats. Rats treated with these compounds improve memory by about 2-2.5 times compared with the control group. Moreover, this study showed that, among the various combinations of amino acids tested, the compound consisting of 20 mM D-Aspartic acid and 10 mM L-arginine was found to be the most efficient way to improve memory in rodents by improving cognitive activities and memory by about 10 fold compared to control rats. In addition, also the compound consisting of 20 mM D-Aspartic acid and 20 mM L-arginine has efficiently responded to the increase of memory both in animals and humans.
The study on humans showed that in all patients treated with the combination of D-aspartic acid and L-arginine there was a memory recovery of 60-70%.
Therefore, it is a specific object of the present invention a combination comprising, or consisting of, D-Aspartic acid and L-Arginine and/or L- Aspartic acid or their salts for simultaneous, separate or sequential use in the treatment for restoring of and/or improving cognitive activities and memory in short and long period.
The invention also concerns a pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or their salts, as active ingredients, in combination with one or more exci- pients and/or pharmaceutically acceptable adjuvants, for use in the treatment for restoring of and/or improving cognitive activities and memory in short and long period.
The combination and the pharmaceutical composition according to the present invention can be used both in the treatment of dementia such as dementia senile and Alzheimer's disease in order to restore and im-
P T/IT2011/000411
8
prove cognitive activities and memory and as supplements to increase the memory, for example in case of school exams, competitions etc.. The dementia may be by vascular origin or by different origin. Moreover, since L- Aspartic acid is one of the main amino acids of the nervous system and since the L-Arginine has properties on the restoration of memory, the invention also concerns the association consisting of a combination of L- aspartic acid and L-arginine or salts thereof for simultaneous, separate or sequential use in the treatment to restore and/or improve cognitive activities and memory in the short and long period, for example in the treatment of dementias such as dementia senile and Alzheimer's disease.
The combination or pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may contain a percentage of D-Aspartic acid or L-arginine or L-aspartic acid or salts thereof, which varies from 0.1% to 99.9% compared to the total of said D-aspartic acid and L-arginine or said D-aspartic acid and L-aspartic acid or salts thereof.
The combination or pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention, can be administered in one or more daily doses, each dose comprising from 0,1 g to 10 g of D- Aspartic acid, 0.1 g to 10 g of L-Arginine and/or 0.1 g to 10 g L-Aspartic acid or salts thereof.
The combination or pharmaceutical composition comprising or con- sisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may further comprise one or more basic or acidic substances in suitable amounts to bring the pH to neutrality.
The combination or pharmaceutical composition comprising or con- sisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts
thereof for use according to the present invention may contain salts of D- Aspartic acid or L-Aspartic acid selected from the group consisting of salts of Sodium, Potassium, Calcium, Magnesium, Zinc, Selenium, Copper, Manganese, Iodine.
Moreover, the combination or pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may further comprise at least an amino acid selected from the group consisting of D- or L-glutammic acid; D- or L-asparagine; D- or L-glutamine; D- or L- serine; D- or L-alanine, D- or L-threonine; D- or L-hystidine, D-arginine; D- or L-cysteine; D- or L-cystine; D- or L-valine; D- or L-methionine; D- or L-tyrosine; D- or L-phenylalanine; D- or L-isoleucine; D- or L-leucine; D- or L-tryptophan; D- or L-carnitine; propionyl-L or D-carnitine; D- or L- acetyl-carnitine; L-carnitin fumarate; carnosine; melatonine; theanine, or salts thereof. The amino acids may be employed as such or as compounds salified with one of the following basic ions: Na, K, Ca, Mg and carbonate, or acid ions. CI, bicarbonate ion, etc.
The combination or pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may further comprise a ketoacid, such as, e.g., for example, alpha-oxalacetic acid, alpha- ketoglutaric, etc, or a salt thereof.
According to a further aspect, the combination or pharmaceutical composition of the invention may include at least one water-soluble and/or liposoluble vitamin.
Among the water-soluble vitamins the following may be mentioned:
Vitamin B1 (thiamine),
Vitamin B2 (riboflavin)
Vitamin B3 or Vitamin PP (niacin or nicotinic acid)
Vitamin B5 or Vitamin W (pantothenic acid)
Vitamin B6 or Vitamin Y (pyridoxine or pyridoxamine or pyridox- al)
Vitamin B8 or Vitamin H (biotin)
Vitamin B9 or Vitamin M (folic acid)
Vitamin B12 (cobalamin)
Vitamin C (ascorbic acid)
Among the liposoluble vitamins the following may be mentioned:
Vitamin A (retinol and analogues)
Vitamin D (ergocalcipherol D2 and colecalcipherol D3)
Vitamin E (tocopherol)
Vitamin K (naphthoquinone and derivatives).
The combination or pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may further comprise at least one antioxidant selected the group consisting of coenzyme Q-10, ascorbic acid, folic acid, alpha-lipoic acid, glutathione, inosidol, tocopherols, tocotrienols (Vitamin E), superoxide dismutase, lycopene, ellagic acid, melatonin.
In addition, the combination or pharmaceutical composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to the present invention may further comprise at least one metal ion selected from the group consisting of magnesium, zinc, selenium, sodium, potassium, calcium, in the form of chlorides, sulphates, fluorides, or in the form of metal oxides.
The present invention will be now described by way of non- limitative illustration according to some preferred embodiments thereof, with particular reference to the figures of the annexed drawings wherein:
Figure 1 shows the composition and the stereo-chemical configu-
IT2011/000411
11
ration of D-Aspartic acid (D-Asp) and L-Aspartic acid (L-Asp) molecule.
Figure 2 shows the concentration of D-aspartic acid in various regions of brain with Alzheimer's disease and normal brain (control). The values of the figure refer to the concentration of D-Aspartic acid assessed in the total homogenate of the brain tissue.
Figure 3 shows an example of separation of D-Aspartic acid and L-Aspartic acid from other amino acids by HPLC. The figure shows a typical chromatogram run by HPLC of a mixture of standard amino acids consisting of 20 pmoles of D-aspartic acid and 100 pmoles di L- Aspartic acid and other L-amino acids (L-Glu, L-Ser, L-His, L-Thr, Gly, L-Arg, L-Ala, L-Tyr, L-Val, L-Met, L-lle, L-Leu, L-Phe and L-Lys), deriva- tized with OPA-NAC (ortho-phthaldialdehyde-N-acetyl-L-Cysteine). D- Aspartic acid is separated from other amino acids and can be quantified on the basis of the peak area.
Figure 4 shows synaptosomes and synaptic vesicles from human brain. The figure shows a typical example of synaptosomes and synaptic vesicles purified from human brain of a healthy person of 30 years. The synaptosomes (0.8-1.5 m in size) represent the peripheral ends of the neuron and are filled with synaptic vesicles (40-70 nm in size) con- taining the chemical neurotransmitters.
Example 1: Study on the role of D-Aspartic acid and L-Aspartic acid in restoring memory in patients with Alzheimer's disease and dementia senile
The study carried out is divided into the following phases:
1) Demonstrating that in human brain D-Aspartic acid is present in synaptic vesicles (subcellular particles of nerve endings containing chemical neurotransmitters which are involved in synaptic transmission), there is a mechanism of D-Aspartic acid synthesis in neurons starting from L- Aspartic acid; neurons possess receptors specific for D-Aspartic acid, and
which are responsible for communication between neurons.
2) Proving that the use of D-Aspartic acid in patients with Alzheimer's disease increases cognitive skills and memory.
1.1 Method for determining D-Aspartic acid by HPLC
The determination of D-Aspartic acid and other amino acids in the human brain was carried out by modifying the method described in (27) as follows. 0.5 g of the human brain (Alzheimer's or normal) of the frontal region was homogenized in 0.2 M perchloric acid in a 1 :10 ratio, then centri- fuged at 13,000 rpm for 5 min. 10 μΙ of the supernatant (sample) are mixed with 200 μΙ of 0.2 M borate buffer, pH 10.0 and 20 μΙ of OPA-NAC (OPA- N-acetyl-cysteine, consisting of 20 mg of OPA and 10 mg of N-acetyl- cysteine in 2 ml of 50% methanol), 2 min after add 900 I of distilled H2O and then 100 μΙ of this mixture is injected on the HPLC column (High Liquid Chromatography) using a running program consists of a solution A (ci- trate phosphate, 0.03 M pH 5.3 containing 5% acetonitrile) and solution B (comprising 90% acetonitrile). The run program was: 0-10% B in 10 min, then 10-100% B in 7 min, then 100% B in 5 min and 0% B in 1 min. With this program, D-Asp acid exits at an elution time of 5.5 min followed by L- Asp at 6.2 min and L-Glu at 8.0 min and then by other amino acids. As standard was used a mixture consisting of 0.1 mM D-aspartic acid and 0.2 mM of other amino acids instead of the sample. The same procedure was carried out to evaluate the concentration of D-Asp and other amino acids in the homogenate of the whole human brain with Alzheimer's and control and in the synaptic vesicles isolated from these brain tissues. In this case, 100 μΙ of a suspension of synaptic vesicles obtained as described in the next section were homogenized with 100 μΙ of 0.2 M perchloric acid and centrifuged as above and the supernatant used as a sample for the determination of amino acids. The brains of Alzheimer's patients and normal brains were obtained post-mortem by organ bank from Loyola University of Chicago (USA). In Figure 3 is shown a typical example of the evaluation
of D-Asp acid and other amino acids (Fig. 3).
1.2 Determination of D-Aspartic acid in human brain and in synaptic vesicles from brains of Alzheimer's patients and healthy persons
The purpose of this experiment is to see if D-Aspartic acid is present as a neurotransmitter in the synaptic vesicles (subcellular particles of neuron endings of 40-60 nm in size) and if there is a difference in concentrations between Alzheimer's brain and control brain. In order to isolate synaptic vesicles, the isolation of synaptosomes was carried out, 0.8-1.5 pm circular biological structures which represent the terminal part of nerve endings (dendrites). They are obtained by homogenization of nerve tissue with a solution of iso-osmotic sucrose. The synaptosomes contain synaptic vesicles that are rich in chemical neurotransmitters such as acetylcholine, L-glutamic acid, L-Aspartic acid, serotonin, GABA, etc.. The preparation of synaptosomes was performed as follows: 1 g of brain tissue was homogenized in 20 ml of 0.32 M sucrose in 0.05 M Tris-HCI, pH 7.5 with a potter homogenizer with a piston - glass walls gap of 15-20 A. The homogenate was then centrifuged at 1 ,000 g for 10 min and the supernatant was centri- fuged at 22,000 g for 20 min. The resulting precipitate was taken up in 4 ml of sucrose 0.32 M and layered on a sucrose gradient consisting of 20 ml of 1.2 M sucrose and 20 ml of 0.8 M sucrose and then centrifuged at 22,000 g for 2 hours. The synaptosomal fraction of the visible in the interface between the solution 1.2 M and 0.8 M sucrose was collected and diluted with an equal volume of physiological buffer (125 mM NaCI, 3 mM KCI, 1.2 mM MgS04, 1.2 mM CaCI 2, 1.2 mM NaH2P04, 22 mM glucose, 10 mM Na2HC03 pH 7.4) and centrifuged for 90 min at 22,000 g. The pellet (synaptosomes) was taken up in 400 μΙ of 0.32 M sucrose, pH 7.4 and layered on a second gradient consisting of 5 ml of 1.2 M sucrose, 5 ml of sucrose 0.95 M sucrose and 5 ml of 0.75 M, respectively, and centrifuged at 22,000 g for 90 min. The synaptosomal fraction located in the interface
between 0.95 M and 0.75 M sucrose was collected and diluted in 4 ml of physiological buffer and analyzed by electron microscopy. For the preparation of synaptic vesicles (SV), 3 ml of the suspension of synaptosomes were diluted with 30 ml of distilled H20 to break the synaptosomes by os- mosis (vesicles being too small will not break) and allowed to stir for 30 min. Then centrifugation at 22,000 g for 20 min was carried out and the pellet consisting of purified synaptic vesicles was taken up in 0.5 ml of
0.9% NaCI. A portion of the pellet was used for morphology with electron microscopy and part was used for the analysis of D-Aspartic acid content. For this purpose, the pellet of synaptic vesicles was homogenized with a double volume of 0.2 M perchloric acid (to disrupt the vesicles and recover the amino acids contained therein) and centrifuged for 5 min at 22,000 g. The supernatant was then analyzed by HPLC for the content of D-aspartic acid and other amino acids. Fig 4 shows an example of a preparation of synaptosomes and synaptic vesicles from normal human brain, while Table 1 shows the concentration of D-aspartic acid and other amino acids in the homogenate of the brain as a whole and synaptic vesicles obtained from the brains of Alzheimer's patients and healthy patients. The results of this experiment shows that D-Aspartic acid is present in the brain in very small amounts compared to other amino acids, but in synaptic vesicles it presents high concentrations in comparison with other amino acids present in the vesicles (Table 1). Thus, this fact means that D-aspartic acid which is found in the brain is all concentrated in the synaptic vesicles,
1. e. in those sub-cellular structures containing the chemical neurotransmit- ters. This concentration pattern is similar to what occurs for acetylcholine and unlike the L-glutamic acid. For instance, acetylcholine in the brain is also located mainly in the synaptic vesicles and as such serves as a neurotransmitter, on the contrary L-glutamic acid has high concentration throughout the nervous tissue including synaptic vesicles. Clearly, L- glutamic acid plays a metabolic role as well as a role of neurotransmitter.
In conclusion, D-aspartic acid can be considered a new chemical neurotransmitter involved in learning and memory processes, because as is shown later, the assumption of an integration based on D-Aspartic acid improves memory in Alzheimer's patients (see below). To confirm this hy- pothesis it is demonstrated that D-Aspartic acid content in the brain of Alzheimer's patients is significantly reduced compared to the brains of control patients. Table 1 shows the concentration of D-aspartic acid (D-Asp), L- aspartic acid (L-Asp) and L-glutamic acid (L-Glu) in the frontal area of the brain of Alzheimer's and normal patients and within synaptic vesicles ob- tained by the same brains
Table 1. D-Aspartic acid content of the frontal zone of human brain and in the synaptic vesicles of healthy people and persons
affected by Alzheimer's disease.
D-Asp L-Asp L-Glu Total
Amino acids
Normal Human Brain
Brain
nmoles/g brain* 35.6+6.4 4.650±450 6.100±740 55.000+5.240
% in respect of total amino acids* 0.064±0.01 8.45±0.82 11.1±1.1 100
nmoles/mg proteins*** 0.45±0.15 54.3±4.5 64.5±6.8 665±50
Synaptic vesicles
nmoles/mg proteins*** 280±25 350±32 420±45 3.300±310
% in respect of total amino acids 8.5+1.0 10.611.2 12.7H . 7 100
Ratio amino acids/mg ****
proteins 622 6.44 6.51
Human Brain with Alzheimer's
Brain
nmoles/g brain** 18.5+5.2 3.900±450 5.750+740 47.300+5.240
% in respect of total amino acids 0.039+0.01 8.2410.92 12.2H .3 100
nmoles/mg proteins*** 0.34+0.15 36.4+4.1 48.4±4.8 540+50
Synaptic vesicles
nmoles/mg proteins*** 205±18 270+30 330+41 2.650+250
% in respect of total amino acids 7.7±1.0 10.1+1.1 12.411.4 100
Ratio amino acids/mg 602 7.41 6.81
proteins
* indicates nmoles of D-Asp, L-Asp, L-Glu and total free amino acids contained in 1 g of homogenate of human brain (obtained from the University of Chiga organ bank). ** Indicates the percent ratio of the concentration of single amino acid in relation to total amino acids. *** indicates nmoles of amino acids relat to 1 mg of total protein (soluble and insoluble) of vesicles sample. **** Indicates the ratio of amino acids expressed as nmol / mg of proteins in the sam used among those contained in purified synaptic vesicles and those contained in the brain homogenate.
1.3 Synthesis of D-Aspartic acid in normal and Alzheimer's human brain.
Since D-Aspartic acid is synthesized in the brain by a D-Aspartate racemase, an enzyme found in some mollusks (28) which transforms L- aspartic in D-aspartic (EC 5.1.1.13), in this study it was investigated whether the isaid enzyme was present or not in the human brain and if there is any difference in enzyme activity between the human brain affected by Alzheimer's disease and human control brain.
The enzymatic assay is based on the following reactions:
1) L-Aspartic acid + D-Aspartate racemase = D-Aspartic acid
2) D-Aspartic acid + 02 + H2O + D-Aspartate oxidase = o oxaloacetate + H2O2 + NH3
3) oc-oxaloacetate + 2,4-dinitrophenilhydrazine = a-oxaloacetate- dinitrophenyl hydrazine (yellow color)
4) a-oxaloacetate-dinitrophenylhydrazine + NaOH= -oxaloacetate- dinitrophenilidrazone complex (strong purple red color).
The process of the enzymatic assay was as follows
0.5 g of Alzheimer's brain or control brain was homogenized (1 :5) in 0.02 M phosphate buffer pH 8.0. Then 500 μΙ of supernatant were mixed with 100 μΙ I of Na L-aspartate 1 M (sample) or 100 μΙ of distilled H20 (blank sample) and 10 μΙ of purified D-aspartate oxidase from rabbit kidney (22) and incubated for 2 hours at 37°C. Then the test mixture was added with 50 μΙ of perchloric acid 5 M, mixed and centrifuged at 13,000 rpm for 5 min. Then 500 μΙ of supernatant was mixed with 100 μΙ of 2.4- dinitrophenylhydrazine (1 mM in 1 M HCI) and left to stand for 20 min at room temperature. Then 200 μΙ of 4 M NaOH was added, mixed and centrifuged at 13,000 rpm for 5 min. The supernatant is read at 445 nm against distilled H20. Finally, the D.O. of the blank sample are subtracted from the D.O. of the sample and D.O. net are index of racemase activity in the brain tissue. For the measurement of enzyme activity it was assumed
that the enzyme activity that produces a color intensity corresponding to 1 OD at 445 nm and in the conditions of enzymatic assay is equal to 1 Enzymatic Unit. As in 100 μΙ of the assay mixture there is an enzyme amount from 20 mg of tissue it follows that 1 g of tissue contains 50 enzymatic units.
Table 2 shows the enzyme units obtained from 1 g of the brains of people suffering from Alzheimer's and from 1 g of the brains of healthy people (control). As it can seen the racemase enzymatic activity in the Alzheimer's brain is significantly reduced and this phenomenon is in agreement with the fact that in the Alzheimer's brain also the content of D- Asp acid is present at concentrations significantly lower than in controls.
Table 2 shows the enzymatic activity of D-aspartate racemase (synthesis of D-Asp acid) in the brains of healthy persons and of patients suffering from Alzheimer's disease.
Table 2. Activity of D-Aspartate racemase in normal and Alzheimer's brains
Enzymatic Units /g of brain tissue
Normal brain Alzheimer's brain
E.U./g E.U./g
Patient n. 1 74 Patient n. 1 55
Patient n. 2 68 Patient n. 2 41
Patient n. 3 59 Patient n. 3 39
Patient n. 4 72 Patient n. 4 45
Patient n. 5 45 Patient n. 5 28
Average±SD 63.6111.8 Average±SD 41.6±9.8
The results were obtained from 5 patients suffering from Alzheimer's disease and 5 persons not affected from this disease. Both groups of people were aged between 70 and 80 years. T-tests (T di Student) between Alzheimer's patients and normal person is P <0.000234
1.4 D-Aspartic acid receptors in human healthy brain and in Alzheimer's brains
The receptors for the chemical neurotransmitter in the nervous system are membrane proteins of the neuron postsynaptic, and constitute the essential elements to capture the input transmitted by the neurotransmitter and then turn them into physiological signals to the cell (visual signals, memory signals, etc.). In the present study it was ascertained whether in the Alzheimer's brain receptors of Aspartic acid were present and if there is a difference of these receptors in Alzheimer's brains compared to control brains. For this purpose affinity (binding) experiments were carried out using radioactive D-Aspartic (D-[3H] aspartic acid) and in accordance with the procedures described in the literature (29), amended as follows: 0.5 g of brain tissue was homogenized 1 :10 in NaCI 0.9%. Centrifuged at 13,000 rpm for 10 min. the supernatant was removed and the precipitate was taken up with 10 ml of 0.9% NaCI. It was centrifuged as above and the washing operation was repeated for 4 more times. The final precipitate was taken up in 2 ml of NaCI 0.9% and the binding assay was carried out on the latter as follows: 100 μΙ of membrane suspension were mixed with 100 μΙ I of D-[3H] aspartate (100 nM) and 300 μΙ 0.05M of phosphate buffer pH 7.4. Then 5.0 pi of each amino acid to be tested at concentrations between 0 and 0.1 mM was added to the assay mixture and incubated for 60 min at 20°C under stirring. Then the sample was centrifuged for 5 min at 13,000 rpm, it was washed 2 more times in phosphate buffer 0.05 m pH 7.4 and then the precipitate was dissolved in 400 μΙ of 0.1 M NaOH. Finally, it was mixed with 3 ml of scintillation fluid and radioactivity was assessed (CPM counts) and the affinity calculated the membranes affinity has been calculated according to the described methods (29). The results obtained are shown in Table 3. As it can seen from the values reported in this table, human brain possesses high affinity receptors towards D- Aspartic acid. D-aspartic acid binds to these specific receptors for this amino acid and not to glutamate receptors. This consideration derives from the fact that the radioactive D-Aspartic acid, which was previously
linked to the membrane, detaches from the same membrane when used in the binding mixture to non-radioactive D-Aspartic acid (cold) and this fact occurs at a very low concentration of D-Asp. On the contrary, the L- glutamic acid and L-Aspartic acid do not have a low affinity in displacing D-Aspartic-membranes bond, thereby indicating that the receptors to which D-Asp is linked are specific receptors for this amino acid. It worth noting that the lower the concentration of cold amino acid displacing the radioactive, the more binding affinity is present. NMDA and others, even at concentrations of 100 mM, are not able at all to move D-Aspartic radioactive binding. This would indicate that these amino acids have no capacity on the D-Asp receptors.
Finally, it is important to note that in Alzheimer's and control brains, the Alzheimer's brain has a significant reduction of these receptors compared to normal brain. In fact, as shown in Table 3, Ki (inhibition constant or affinity constant), which indicates the concentration at which 50% of the binding ties are displaced by cold amino acid, is of 0.45 ± 0.04mM with membranes obtained from Alzheimer's brain and 0:22 ± 0.02 mM in case of membranes obtained from the control brain.
Table 3 shows the activity of D-aspartic acid receptors (displacement of specific bonds for D-[3H] Asp by various amino acids and amino acids analogues on the postsynaptic membranes (PSMS) obtained from the brains of Alzheimer's patients and normal persons).
Table 3
Displacement of D-[3H]Asp binding by various chemical competitors
Brain from Brain from
Control patients Alzheimer's patients
(frontal area) (frontal area)
Binding competitors Κ/ (μΜ) Ki (μΜ)
D-Aspartate 0.22±0.05 0.45±0.04
L-Glutamate 2.4±0.4 3.5±0.4
L-Aspartate 3.5±0.5 5.4±0.6
D-Glutamate 43±8.6 54±10
NMDA >100 >100
Quisqualate >100 >100
Kainate >100 >100
DL-Homocisteate >100 >100
L-Alanine >100 >100
L-Serine >100 >100 The concentration of D-[3H] Asp in the binding assay was 100 nM, and the amino acids or amino acids analogues were 0 to 100 μΜ. The inhibition constant (Ki) indicates the amino acids concentration capable of displacing 50% of the binding ties. The values indicate the mean ± SD obtained from 4 experiments, each carried out on plasma membranes from Alzheimer's or control brains. Values > 00 indicate that the amino acid tested for displacement was completely inactive. The amino acid affinity to membrane receptors is as stronger (specific) as is lower the amino acid concentration which displaced 50% of the bonds of (D-[3H] Asp) to the membranes. 1.5 Accumulation of D-Aspartic acid and L-Aspartic acid in brain and synaptic vesicles in rat after treatment with exogenous D- Aspartic acid
The purpose of this experiment was to know whether D-Aspartic ac-
id orally administered enters or not in the brain and if it is transported into synaptic vesicles in order to explicate its action as a neurotransmitter. The experiment was carried out on adult rats of the Wistar strain (kept in cages and in a suitable environment according to the ministerial regulations). The rats of the first group, consisting of 5 animals, were given to drink a solution of 20 mM sodium D-aspartate. A second group of 5 rats was given to drink sodium L-aspartate at a concentration of 20 mM and finally the third group of 5 rats was given to drink tap water. The duration of treatment was 15 days. At the end of the treatment the rats were sacrificed, the brains were removed and homogenized 1:10 in sucrose 0,32. A portion (1/10) of each homogenate was used for the analysis of amino acids (see section 1.1), and the remainder was used for the preparation of synaptic vesicles according to the procedure described above (see section 1.2). Finally, the content of D-aspartic acid was evaluated in the whole homogenate and in the synaptic vesicles. The results obtained from this experiment are shown in Table 4, and indicate that when a rat is administered orally by sodium D-aspartate at a concentration of 20 mM, the concentration of this amino acid in the brain increases of 2.42 times compared to control (rat who drank tap water). It is interesting to note that at least half (56%) of D- Aspartic acid present in the whole brain is carried into the synaptic vesicles, which represent, in terms of cell mass, about a thousandth of brain tissue mass. Therefore these data show that D-Aspartic acid has a specific role in the synaptic vesicles, namely the role of neurotransmitter. In addition to these data, the results presented in Table 4 show that if the animal drinks the L-aspartic acid in place of D-Aspartic acid, a significantly increased concentration of D-Aspartic acid is also accumulated in the brain and in the synaptic vesicles, compared to control (Table 4). Therefore, This result shows that exogenous L-Aspartic acid as well as the endogenous turns in D-Aspartic acid by an endogenous racemase.
Table 4 shows the concentration of D-Aspartic acid in whole brain
and in synaptic vesicles in rats after the intake of 20 mM D-Asp or 20 mM L-Asp or H20.
Table 4. Concentration of D-Aspartic acid in whole brain and in the synaptic vesicles in rats after the intake of 20 mM D-Asp or 20 mM L-Asp or H20.
Rats groups which drunk 20 mM sodium D-Aspartate
nmoles/g of brain nmoles/mg of proteins
Whole brain* 85±10.5 0.65±0.2
Synaptic vesicles** 48±5.6 620±55
Rats groups which drunk 20 mM sodium L-Aspartate
nmoles/g of brain nmoles/mg of proteins
Whole brain * 48±4.5 5±0.04
Synaptic vesicles ** 24±4.0 ±35
Rats groups which drunk tap water (control)
nmoles/g of brain nmoles/mg of protein
Whole brain * 35±4.2 0.18±0.02
Synaptic vesicles ** 18±3.4 150±18
The values represent the mean ± SD obtained from 5 adult rats treated with 20 mM sodium D-aspartate or 20 mM sodium L-aspartate or tap water (control). * Indicates nmoles of D-Asp contained in 1 g of brain homoge- nate or nmoles referred to the content of 1 mg of the total proteins (soluble and insoluble). ** Indicates nmoles of D-Asp contained in synaptic vesicles prepared from 1 g of brain or the nmoles referred to 1 mg of total proteins (soluble and insoluble).
1.6 Use of D-Aspartate in the recovery of learning and memory in Alzheimer's disease patients
In the light of the results obtained above, it was intuitive to think that oral administration of sodium D-aspartate to persons affected by Alzheimer's disease could improve memory and cognitive status in these patients. Therefore, an experiment was carried out on a group of 6 patients diagnosed with Alzheimer's disease in clinical stage between moderate and severe. These patients were not under any treatment of Alzheimer's
drugs.
Each patient was given orally a solution comprising 10 ml of sodium D-aspartate at a concentration of 2 M (2.66 g of D-Aspartic acid, corresponding to 3.12 g of sodium D-aspartate) mixed in half a glass of water or juice after lunch or dinner. The solution of sodium D-aspartate given to the patient consisted of a dietary supplement approved by the Ministry of Health and covered by a patent and marketed under the trademark DADAVIT ® and used as a supplement for other purposes. The experiment had a duration of 30 days and was carried out under medical control. After this period, some specific symptoms of the Alzheimer's disease (below) have been evaluated and compared with those of the same patients before therapy.
Symptoms used for the current study were as follows and the obtained results are presented in Table 5.
Amnesia: Patients with dementia due to Alzheimer's have good memory of past things but cannot remember recent essential things as, for example, they forget the place where they are, or they do not, for example, remember where is the toilet of their house, etc.
Apraxia. Inability to perform common actions: whistling, making coffee, cooking, doing drawings
Agnosia: The inability to recognize common things e.g. fruit, pets, etc..
Anomia: Inability to name an object, while recognizing it.
Disorientation in time and space: Inability to remember the day or month or season or year, as well as inability to remember the place where he is.
Agraphia: The subject has difficulty in writing. In the most severe forms he cannot even write his own signature.
.Changes in mood: The mood tends to change abruptly in the sub- ject. Depression, euphoria, tears also associated with depression, anxiety, insomnia, agitation.
Language problems: The subject finds difficulty to name an object.
Loss of initiative: Loss of each initiative and interest.
The results obtained in this study, which are presented limited only to 6 patients, give a clear indication that the use of sodium D-aspartate in Alzheimer's patients improved, in all subjects, learning and memory with a recovery of cognitive activities at least of 40-60%. Table 5 shows the evaluation of the recovery status of learning and memory improvement in Alzheimer's patients (moderate to severe) treated with sodium D-aspartate.
Table 5
Amnesia Apraxia Agnosia Anomia Disorientation Agraphia Changes in Language Loss of in time and space mood problems initiative
Patient n. 1 recovery recovery recovery recovery recovery recovery recovery recovery recovery
Male 77 years 40-50% 40-50% 40-50% 50-60% 60-70% 30^0% 50-60% 40-50% 30-40% seriousness =moderate
Patient n. 2 recovery recovery recovery recovery recovery recovery recovery recovery recovery
Male 80 years 45-55% 45-55% 40-50% 45-65% 55-65% 35-45% 60-665% 35-45% 45-55% seriousness =moderate
Patient n. 3 recovery recovery recovery recovery recovery recovery recovery recovery recovery
Male 74 years 30-40% 25-35% 35-45% 35-45% 45-55% 25-35% 40-50% 30-40% 25-35% seriousness =severe
Patient n. 4 recovery recovery recovery recovery recovery recovery recovery recovery recovery
Female 81 years 55-65% 55-65% 55-65% 55-65% 50-60% 45-55% 45-55% 55-65% 35-45% seriousness =moderate
Patient n. 5 recovery recovery recovery recovery recovery recovery recovery recovery recovery
Male 79 years 35-45% 35-45% 35-45% 55-65% 45-55% 45-55% 65-75% 70-80% 35-45% seriousness =moderate
Patient n. 6 recovery recovery recovery recovery recovery recovery recovery recovery recovery Male 81 years 20-30% 20-30% 20-30% 35-45% 35-45% 0-30% 30-40% 35-45% 25-35% seriousness =severe
The evaluation is expressed in terms of recovery of that specific function in comparison with same age persons not affected by Alzheimer's (value=10
Conclusions on the studies carried out
In conclusion, the experimental results obtained so far show that D- Aspartic acid is present in endogenous form in human and rat brains and that there is an enzyme system for the synthesis of D-Aspartic and mem- brane receptors for this amino acid and that D-aspartic acid is able to induce improvement in learning and memory in persons affected by Alzheimer's disease.
EXAMPLE 2: Study on the effects of amino acids and their combination on learning and memory in rats
For these experiments, rats were used as an animal model as they possess a biological system which is considered very similar to that of humans. So, it is believed that such biological effects induced in rats by a substance will be present also in humans.
In this specific case a study was carried out on rats in order to evaluate:
1) The effect of treatment with the following amino acids on rats: (i) D-Aspartic acid, (ii) L-Aspartic acid, (iii) L-Arginine, (iv) a combination consisting of D-Aspartic acid and L -Aspartic acid and (iv) a combination consisting of D-Aspartic acid and L-Arginine, on increasing learning activity and memory in rats.
2) The effect of treatment with the following amino acids on rats: (i) D-Aspartic acid, (ii) L -Aspartic acid, (iii) L-Arginine, (iv) a combination consisting of D-Aspartic acid and L -Aspartic acid and (iv) a combination consisting of D-Aspartic acid and L-Arginine, on the accumulation of the same in the brain and in the synaptic vesicles.
3) The effect of treatment with the following amino acids on rats: (i) D-Aspartic acid, (ii) L -Aspartic acid, (iii) L-Arginine, (iv) a combination consisting of D-Aspartic acid and L -Aspartic acid and (iv) a combination consisting of D-Aspartic acid and L-Arginine, on any side effects.
For D-aspartate is meant the salt of D-aspartic acid. For L-aspartate is meant the salt of L-aspartic acid.
Principles and Methodology (Test di Water-Maze).
For the study of learning and memory adult rats were used of about 12 months of age, males and females (Wistar). Rats were hold 2-3 per cage, separated by sex, in an environment controlled for temperature (23- 24°C) and humidity (60%), with cycles of daylight and night. The hygienic conditions of housing were in line with international standards of mainten-
1 000411
29
ance of rats. For the experiment in learning and memory the Morris method Water Maze-1984 (R-Morris, 1984) has been used. It consists in the evaluation of learning activity and memory in rats in remembering the position of the floating and not visible platform in a tank water. This method is officially considered the most suitable, because the rat is subjected to a type of learning and memory that involves temporal and spatial memory. In practice, the rat, after finishing the course of treatment with the substance the efficiency of memory of which is to be tested, is IMMERSO into a circular pool of 2 meters in diameter and 50 cm high, filled with water (made opaque wit an addition of milk) and containing a floating platform (10x10 cm) at the center of the tank below the surface of water. Just placed in water, the rat swims randomly to seek support for salvation. After reaching the platform, the rat is left on the platform for about 30 seconds allowing it to store the spatial position of the platform in the tank. Then it is dried and put it in his cage. In the first attempts, the rat takes a long time to find the platform (1.5-2 min), then gradually learns the location of the platform and takes less time to find it. If the drug being tested has an activity on learning and memory, the rat will learn quicker the position of the platform compared to a control rat. In this case, the complete experiment lasted 5 days with 2 sessions per day: one in the morning and evening. For each exercise of Water-Maze time in seconds that the rat employed to reach the platform is relieved. Then, the data were statistically processed (using the test "ANOVA" one-way and two-way) to know the significance of the treatment effect of the compound versus placebo.
1st Experiment: Effect of D-Aspartic acid on learning and memory in rats with Water-Maze.
The experiment was carried out as follows: 5 rats males and 5 rats females drank a solution of 20 mM D-aspartic acid (dissolved in 20 mM NaOH to pH 7.0) for 30 consecutive days. Throughout the treatment the rats were free to drink and eat (food for rats) without limitation. At the thir-
2011/000411
30
ty-first day, each rat was subjected to the experiment of learning and memory with the "Water-Maze" by making 2 attempts per day (10 hours and at 17 hours). To this purpose it was used a circular pool of 2 meters in diameter and 50 cm in height containing water made opaque (by adding milk). At the center of the tank a floating platform was put at 1 cm below the water surface to avoid the rat from seeing. Every day for 5 consecutive days, each rat of the group was placed in the tank (in the same place) and left free to swim until it found the platform on which to lean. After finding the platform the rat was left for 20 sec on the platform allowing him to store the position of the platform. Then the rat was dried and put back in the cage. After each exercise the time that the rat had employed to reach the platform was collected. The Water-Maze experiment was carried out every day at 10 and 18.
2nd Experiment: Effect of L-Aspartic acid in learning and memory in rats with the Water - Maze method.
This experiment of learning and memory using the Water-Maze method has been carried out in the same manner as above, but on other 5 male and 5 female rats which drank, for 30 days, a solution of 20 mM L- Aspartic acid (neutralized at pH 7.0 with 0.1 M NaOH).
3rd Experiment: Effect of the L-Arginine acid in learning and memory in rats with the Water-Maze method.
This experiment of learning and memory using the Water-Maze method has been carried out in the same manner as above, but on other 5 male and 5 female rats which drank, for 30 days, a solution of 20 mM L- Arginine (neutralized at pH 7.0 with 0.1 M HCI).
4th Experiment: Effect of using a combination constituted by D- Aspartic acid and L-Aspartic acid in learning and memory in rats with the Water-Maze method.
This experiment of learning and memory using the Water-Maze me- thod has been carried out in the same manner as above, but on other 5
male and 5 female rats which drank, for 30 days, a solution of 20 mM of D- Aspartic acid and 20 mM L-Aspartic acid (neutralized at pH 7.0 with 0.1 M NaOH).
5th Experiment: Effect of using a combination constituted by 20 mM D-Aspartic acid and 10 mM L-Arginine in learning and memory in rats with the Water-Maze method.
This experiment of learning and memory using the Water-Maze method has been carried out in the same manner as above, but on other 5 male and 5 female rats which drank, for 30 days, a solution of 20 mM of D-Aspartic acid and 10 mM L-Arginine (neutralized at pH 7.0 with sodium bicarbonate 0.1 M).
6th Experiment: Effect of using a combination constituted by 20 mM acido D-Aspartic and 20 mM L-Arginine in learning and memory in rats with the Water-Maze method.
This experiment of learning and memory using the Water-Maze method has been carried out in the same manner as above, but on other 5 male and 5 female rats which drank, for 30 days, a solution of 20 mM of D-Aspartic acid and 20 mM L-Arginine (neutralized with each other).
7th Experiment: Control
This experiment was carried out with the Water-Maze in the same conditions as above but using a different group of rats, 5 males and 5 females of 12 months of age. In this case, the rats drank only tap water. The time in seconds used to reach the platform of this group of control rats was used as time reference for the assessment of learning and memory in the other groups of rats treated with amino acids.
RESULTS OBTAINED FROM LEARNING AND MEMORY EXPERIMENTS.
The results obtained on the effect of the amino acids and their compounds are shown in Tables 6-11. In each table is shown the time taken (in seconds) from each rat of each experimental group and in each
0411
32
of the 5 days and in each period of days to reach the platform in the Water-Maze system. As it has not been observed a significant difference in the time necessary to reach the platform between male and female, the values obtained from both male and female rats have been taken together. The mean and the standard deviation have been evaluated for each exercise of the 10 control rats and of those subjected to different treatments with different amino acids. Finally, the value of Student's T (T test) has been calculated on each experimental group of rats versus the control group. This statistical study revealed the following:
1) L-Aspartic acid alone does not improve learning and memory in rats. Indeed, the comparison of the average time in seconds to reach the platform and of the value P of StudentT, shows that the rats improve the time to reach the platform in the progressive days of exercise, but this improvement is not different from that of controls (Table 6). For each day of experiment, the value of P is always greater than 0.1 (P> 0.1). As to be significant, the P value should be less than 0.05 (P <0.05) (Table 7).
Table 6. Learning and memory experiment of rats treated with tap water (control) with the Water-Maze method
Time in seconds employed by the rat to reach the platform
Day of experiment 1st dav 2nd dav 3rd dav 4th dav 5th dav
Time of experiment 10 18 10 18 10 18 10 18 10 18
Male 1 172 160 148 156 130 122 102 98 44 42
2 142 148 134 128 107 99 69 51 38 31
3 150 144 152 124 109 102 76 64 52 34
4 162 144 154 133 111 96 78 72 44 45
5 155 143 132 123 96 92 68 65 56 44
Female 1 165 160 143 145 125 112 99 102 65 54
2 169 161 154 133 114 115 102 91 65 53
3 163 162 133 129 104 98 99 87 51 44
4 176 154 154 162 134 131 111 93 66 55
5 122 151 102 98 98 88 91 82 61 31
Average 157 152 141 133 123 106 90 81 55 44
±SD ±16 ±8 ±16 ±18 ±13 ±14 ±15 ±17 ±9 ±8
In this experiment rats was used which drank tap water (control) instead of an amino acid (see experimental part, section 1.7). Then the learning and memory experiment began using the Water-Maze system. This method consisted in placing the rat in a tank of 2 m in diameter with a central platform containing opaque water and the time that the rats employed to reach the platform were collected. This experiment was carried out 2 times a day (at 10.00 and at 18.00) and for 5 consecutive days. Finally, the average and SD of the time in seconds for the 10 rats at each water-maze experiment was calculated.
Table 7. Learning and memory experiment of rats treated with L- aspartic acid with the Water-Maze method
Time in seconds employed by the rat to reach the platform
Day of experiment 1st dav day 3rd dav 4th dav 5th dav
Time of experiment 10 18 10 18 10 18 10 18 10 18
Male 1 160 175 160 155 130 120 60 55 35 30
2 155 150 145 135 110 105 75 65 44 50
3 180 172 144 132 124 114 86 74 42 40
4 162 148 142 150 108 100 96 90 64 44
5 180 175 165 142 124 120 98 86 45 35
Female 1 134 132 125 115 110 110 90 85 54 45
2 174 180 175 145 115 95 78 64 46 35
3 158 156 135 124 110 88 85 76 55 42
4 145 152 135 120 98 86 44 56 28 26
5 164 154 132 144 120 110 86 64 52 48
Average 161 159 146 136 115 105 80 72 47 40
±SD ±14 ±15 ±16 ±13 ±9 ±12 ±16 ±12 ±10 ±8
Student's t test (P) >0.5 >0.5 >0.4 >0.4 >0.4 >0.3 >0.4 >0.2 >0.1 >0.3
The rats drank a solution of 20 mM L-Aspartic acid for 30 days (see experimental part, section 1.7). Then the learning and memory experiment began using the Water-Maze system. This method consisted in placing the rat in a tank of 2 m in diameter with a central platform and containing opaque water and the time that the rats employed to reach the platform were collected. This experiment was carried out 2 times a day (at 10.00 and at 18.00) and for 5 consecutive days. Finally, the average and SD of 10 rats for each experiment was calculated and the significance of differences of time in seconds to reach the platform was calculated using the Student's T. A Student's T value, P <0.05 was assumed statistically valid.
2) L-Arginine alone produces a good improvement in learning and memory in rats. Indeed, from a comparison of the average time in seconds to reach the platform and the value P of Student-T obtained by comparing the times of rats treated with L-arginine and those treated with placebo, it is evident that rats improve the time to reach the platform only on day 5 after which they were subjected to the exercise of Water-Maze (values in Table 8 against values in Table 6). On Day 5 the value P of Student-T is <0,001 both at the cycle at 10 a.m. and 18 p.m. (Table 8).
Table 8 Learning and memory experiment of rats treated with L-Arginine with the Water-Maze method
Time in seconds employed by the rat to reach the platform
Day of experiment 1st dav 2nd dav 3rd dav 4th dav 5th dav
Time of experiment 10 18 10 18 10 18 10 18 10 18
Male 1 174 164 144 150 110 102 82 75 25 22
2 144 140 130 124 105 96 66 48 26 18
3 155 160 155 135 85 86 55 54 30 13
4 172 155 162 154 112 100 80 74 25 25
5 140 134 123 115 98 102 96 68 28 26
Female 1 155 164 146 155 110 102 98 96 41 30
2 178 166 175 143 1 12 110 96 97 38 27
3 143 132 124 125 86 98 90 90 33 20
4 155 150 160 172 140 136 87 90 20 15
5 146 152 132 121 1 12 106 97 88 25 10
Average 156 152 145 139 107 104 82 78 24.9 20.6
±SD ±13 ±12 ±17 ±18 ±15 ±13 ±17 ±17 ±7.7 ±6.5
Student's t test (P) >0.5 >0.5 >0.4 >0.4 >0.4 >0.3 >0.2 >0.1 <0.001 <0.001
The rats drank a solution of 20 mM L-Arginine for 30 days (see experimental part, section 1.7). Then the learning and memory experiment began using the Water-Maze system. This consisted in placing the rat in a tank of 2 m in diameter with a central platform and containing opaque water and the time that the rats employed to reach the platform. This experiment was carried out 2 times a day (at 10.00 and at 18.00) and for 5 consecutive days. Finally, the average and SD of 5 male and 5 female rats for each experiment was calculated. Finally, it has been calculated the average and SD of 10 rats for each experiment and the significance of differences of time in seconds to reach the platform was calculated using the Student's T.. A Student's T value, P <0.05 was assumed statistically valid.
3) D-Aspartic acid produces a good improvement in learning and memory in rats. Indeed, a comparison of the average time in seconds to reach the platform, and the value of P of Student'T, shows that up to the first attempt of the 4th day of testing with Water-Maze system there were no significant improvements in learning and memory compared with rats in the control group (P value of Student'T is always greater than 0.05 , P> 0.05). However, the second attempt of 4th day, it has been observed that the rats reached the platform with times statistically significant compared to the same day of the controls (see values from Table 9 compared to the values of Table 6). This value of such significant learning is also confirmed in the two sessions of Day 5th where, for both sessions, the value P is always less than 0.001 (P <0.001) (Table 9).
Table 9. Learning and memory experiment of rats treated with D-Aspartic acid with the Water-Maze method
Time in seconds employed by the rat to reach the platform
Day of experiment 1st dav day 3rd day 4th day 5th day
Time of experiment 10 18 10 18 10 18 10 18 10 18
Male 1 150 150 140 130 112 85 75 35 9 8
2 145 160 150 130 120 97 99 44 14 13
3 155 160 155 135 1 15 05 101 50 19 15
4 170 175 165 160 104 1 13 103 46 14 14
5 160 150 145 133 110 102 87 44 26 23
Female 1 150 145 130 135 125 98 64 35 18 15
2 170 165 155 130 131 103 74 40 26 23
3 135 155 114 1 15 105 90 71 30 23 19
4 190 185 150 130 110 102 98 32 26 24
5 135 150 120 110 100 100 78 30 28 23
Average 156 159 142 131 113 99 85 38 20 18
±SD ±17 ±12 ±16 ±18 ±10 ±8 ±14 ±7 ±6 ±5
Student's t iest (P) >0.3 >0.1 >0.3 >0.3 >0.4 >0.1 >0.29 <0.001 <0.001 <0.001
The rats drank a solution of 20 mM D-Aspartic acid for 30 days (see experimental part, section 1.7). Then the learning and memory experiment began using the Water-Maze system. This consisted in placing the rat in a tank of 2 m in diameter with a central platform and containing opaque water; the time that rats employed to reach the platform has been measured. This experiment was carried out 2 times a day (at 10.00 and at 18.00) and for 5 consecutive days. Finally, it was calculated the mean and SD of 5 male and 5 female rats for each experiment. Finally, it has been calculated the average and SD of 10 rats for each experiment and the significance of differences of time in seconds to reach the platform was calculated using the Student's T.. A Student's T value, P <0.05 was assumed statistically valid.
4) The composition consisting in D-Aspartic acid and L-Aspartic acid produces a good improvement on learning and memory in rats, but less than using D-Aspartic acid alone (see the P values of Student's T- on the fifth day of experiment). In the first 4 days of exercise of rats in the Water-Maze any significant change in the times to reach the platform does not occur in these rats compared to control group (Table 6). However, even in this case, the times that the rats used on 5th day in reaching the platform were significantly different from the control group value of a Student's T, P <0.001 both in morning test at 10am and in the evening test at 6 pm (Table 10).
Table 10. Learning and memory experiment of rats treated with a combination of D-Aspartic acid + L-Aspartic acid with Water-Maze method
Time in seconds employed by the rat to reach the platform
Day of experiment 1st dav 2nd dav 3rd dav 4th dav 5th day
Time of experiment 10 18 10 18 10 18 10 18 10 18
Male 1 155 145 134 135 90 75 34 32 20 16
2 164 160 155 144 97 77 44 42 25 22
3 166 155 165 143 112 100 76 56 33 30
4 172 187 174 166 130 133 122 90 46 44
5 161 149 140 143 121 119 90 88 61 39
Female 1 165 144 138 138 98 97 64 65 46 48
2 130 131 158 169 130 132 98 91 55 53
3 138 135 124 135 122 1 10 76 80 61 55
4 121 142 151 148 130 121 110 96 56 45
5 134 133 110 102 98 81 64 56 43 41
Average 150 148 149 142 1 13 104 78 69 45 39
±SD ±18 ±16 ±19 ±18 ±16 ±22 ±27 ±22 ±14 ±13
Student's T test (P) >1 >1 >1 >0.5 >0.5 >0.5 >0.1 >0.1 <0.01 <0.01
The rats drank a solution of 20 mM D-Aspartic acid + 20 mM L-Aspartic acid for 30 days (see experimental part, section .7). Then the learning and memory experiment began using the Water-Maze system. This test consisted in placing the rat in a tank of 2 m in diameter with a central platform and containing opaque water; the time that rats employed to reach the platform has been measured. This experiment was carried out 2 times a day (at 10.00 and at 18.00) and for 5 consecutive days. Finally, was calculated the mean and SD of 5 male and 5 female rats for each experiment. Finally, it has been calculated the average and SD of 10 rats for each experiment and the significance of differences of time in seconds to reach the platform was calculated using the Student's T.. A Student's T value, P <0.05 was assumed statistically valid.
5) The composition consisting of D-Aspartic acid, 20 mM and 10 mM L-arginine improves very significantly the learning and memory in rats and the efficiency of this compound is much higher even than the improvement induced by D Aspartic acid or by the compound including D- Aspartic acid or by L-Arginine or by L-Aspartic acid. In fact, as shown in Table 11 , after the rats were treated with the compound consisting of D- Aspartic acid and L-Arginine, the rat has learned a lot before the other treatments the position of the platform. The comparison of times for rats to reach the platform after treatment with the composition consisting of D- Aspartic acid and L-arginine (Table 11) with those of the times of the control rats (Table 6) is observed already in the session of 3rd day of the Water-Maze times are significantly reduced so that the P value of Student's T is highly significant (P <0.001) in respect of the times spent by control rats (See the results of Table 11 in respect of the results of Table 6, control). In addition, the improvement in learning and memory was always higher by increasing the number of the attempts so that on the 5th day of testing in the Water Maze system, rats employ an average of just 5 seconds to reach the platform.
Much more specifically, the group of rats that were treated with D- Aspartic acid or with the combination D-Aspartic acid and L-Aspartic acid, on the fourth day of the test still show no increase in memory compared to control: only at the fifth day of the test there was an increase of the memory of 2-2.5 times (expressed as the ratio of times to reach the platform). Instead, the group of rats treated with the compound consisting of D- Aspartic acid and L-Arginine, on the fourth day of test showed an improvement of memory by about 4 times on the control and on the fifth day showed an improvement of about 9 -10 times compared with the control group (expressed as the ratio of times to reach the platform).
Table 11. Learning and memory experiment of rats treated with a combination of D-Aspartic acid + L-Arginine with Water-Maze method
Time in seconds employed by the rat to reach the platform
Day of experiment 1st dav dav 3rd dav 4th day 5th dav
Time of experiment 10 18 10 18 10 18 10 18 10 18
Male 1 150 150 140 130 80 50 20 10 3 3
2 145 160 150 130 75 55 15 8 3 4
3 155 160 155 135 85 50 25 15 7 5
4 170 175 165 160 75 70 15 5 4 4
5 160 150 145 133 110 75 22 12 6 6
Female 1 150 145 130 135 90 70 30 22 6 5
2 170 165 155 130 80 65 20 16 4 3
3 135 155 114 115 70 40 10 6 3 3
4 190 185 150 130 100 74 22 14 6 4
5 135 150 120 110 100 84 18 16 6 6
Average 156 160 142 131 87 63 20 12 5 5
±SD ±17 ±12 ±16 ±13 ±13 ±14 ±6 ±5 ±1.7 ±1.5
Student's T test (P) >0.4 >0.40 >0.3 >0.3 <0.001 <0.001 <0.001 <0.001 <0.001 <0.0(
The rats drank a solution of 20 mM D-Aspartic acid + 10 mM L-Arginine for 30 days (see experimental part, section 1.7). Then the learning and memory experiment began using the Water-Maze system. The test consisted in placing the rat in a tank of 2 m in diameter with a central platform and containing opaque water; the time that rats employed to reach the platform has been measured. This experiment was carried out 2 times a day (at 10.00 and at 18.00) and for 5 consecutive days. Finally, the average and SD of 10 rats for each experiment it has been calculated and the significance of differences of times in seconds to reach the platform was calculated using the Student's T.. A Student's T value, P <0.05 was assumed statistically valid
P T/IT2011/000411
43
6) The composition consisting of 20 mM D-Aspartic acid and L- arginine 20 m'M also very significantly improves learning and memory in rats with efficiency comparable to the composition consisting of D-Aspartic acid, 20 mM and 10 mM L-arginine (for the latter composition the times of the rats for reaching the platform are not reported in the table, because the P values of Student's T are in practice the same as those shown in Table 11).
CONCLUSION ON THE STUDIES CARRIED OUT ABOVE
The conclusion of the experimental studies carried out on rats, about the effect of D-Aspartic acid, L-Aspartic Acid, L-Arginine, and the combinations consisting of D-Aspartic acid and L-Aspartic acid and the composition consisting of D-Aspartic and L-arginine on learning and memory is as follows:
a) L-Aspartic acid alone did not show any effect on learning and memory.
b) D-Aspartic acid or L-arginine or the combination of D-Aspartic acid with L-Aspartic acid induce a good positive effect on increasing learning and memory in rats. Rats treated with these compounds improve memory by about 2-2.5 times compared with the control group.
c) The combination consisting of D-Aspartic acid and L-Arginine, both the association of 20 mM D-Aspartic acid and 10 mM L-arginine and the association of 20 mM D-Aspartic acid and 20 mM L-arginine, induces a very high increase in learning and memory which is about 10 times compared with the control group. This result indicates, therefore, that these last two are by far the best associations of compounds for the treatment of memory in rats and therefore also on human.
EXAMPLE 3: Study on the effects of the treatment with D-Aspartic acid, L-Aspartic Acid, L-Arginine, with a combination consisting of D- Aspartic acid and L-Aspartic acid, and with a combination consisting of D- Aspartic Acid and L -arginine about their build up in the brain and in the synaptic vesicles
This study was conducted in order to know the concentration of D- Aspartic acid, L-Aspartic acid and L-arginine in the brain and in the synaptic vesicles after treatment of rats for 30 days by each of these amino acids and the concentration of the combination consisting of D-Aspartic acid and L-Aspartic acid, and of the combination consisting of D-Aspartic acid and L-arginine. To this aim, after several experimental groups of rats had finished the learning and memory experiment using the-Water-Maze system, they were sacrificed and their brains have been collected. Then a mid-portion of the brain has been used for the determination of amino ac- ids by HPLC (Ref. 27 and 28) (see section 1.1) and the other half portion was used for the preparation of synaptic vesicles (see paragraph 1.2 ). The results obtained from this study are shown in Table 12. This table shows the concentrations and SD obtained from the 10 rats for each experimental group made by 5 males and 5 females.
As it can be seen from the same table, D-Aspartic acid is usually present in the endogenous form in the brain and in synaptic vesicles of rats. In the brains of control rats (i.e. rats that drank only tap water) the concentration of D-aspartic acid is on average 35 ± 5 nmoles / g of brain (4.65 ± 0.66 pg / g). However, a substantial amount of D-Aspartic acid, corresponding approximately to 10-15% of the total amount that is located in synaptic vesicles, i.e., in the cell structures that are rich in neurotransmitters and that are localized at the nerve endings of neurons (dendrites). This is very important because in these structures are located the neurotransmitters from the neuron cell body. Neurotransmitters are molecules that following nerve or electrical stimulus are transferred from pre-synaptic neuron to post-synaptic neuron creating cell information which are at the base of learning and memory processes. Normally in synaptic vesicles, the
P T/IT2011/000411
45 concentration of D-Aspartic reported as the content of amino acid/mg of protein is about 300 times higher than the brain (Table 12).
Table 12. Concentration of D-Aspartic acid, L-Aspartico acid and L- Arginine in the brain and in the synaptic vesicles in rats treated with control
Concentration in the brain Concentration in the
synaptic vesicles
(nmoles/g of brain) (nmoles/mg of proteins)
Rats treated D-Asp L-Asp L-Arg D-Asp L-Asp L-Ar£ with:
Tap water 35 5600 1600 285 510 20
±5 ±460 ±210 ±30 ±55 ±5
L-Aspartate 45 5.800 1550 310 520 25
±6 ±490 ±180 ±55 ±54 ±8
L-Arginine 34 5530 1580 265 490 27
±7 ±450 ±205 ±35 ±60 ±6
D-Aspartate 85± 5750 1530 565 520 15
±12 ±530 ±195 ±46 ±45 ±5
D-Aspartate 95 5750 1760 510 515 18
+L-Aspartate ±13 ±495 ±160 ±52 ±52 ±7
D-Aspartate 120 5340 1730 585 515 19
+L-Arginine ±18 ±410 ±182 ±59 ±48 ±8
The concentration of amino acids in synaptic vesicles is expressed in terms of nmoles/mg of vesicular protein. The determination of amino acids was carried out using HPLC methods described in section 1.1. The preparation of synaptic vesicles from rat brain was performed as described in section 1.2. The results refer to the average ± SD obtained from 5 adult males and 5 adult females.
When rats were treated with D-Aspartic acid (in the form of sodium D-aspartate), this amino acid accumulates significantly in the brain and synaptic vesicles and its concentration in these tissues increases the value of about 2.8 times compared to that in the brain and vesicles from con- trol rats. This fact indicates therefore that D-Aspartic acid ingested can pass the blood brain barrier, enter the neurons of the brain and move into synaptic vesicles where acts as a neurotransmitter chemical (Table 12). By a comparative study of the maximum concentration of D-Aspartic synaptic acid in the brain and in vesicles occurs when the animal ingests the compound consisting of D-Aspartic acid and L-arginine, where the concentration may be as high as 120 nmol / g in whole brain and 585 nmol /mg protein in synaptic vesicles. Therefore, this result indicates that the combination of D-Aspartic acid and L-Arginine is the most efficient compound to introduce D-Aspartic acid in the brain and therefore also the compound that gives more brain activity and that validates the results obtained in experiments on memory above mentioned.
With regard to the concentration of other amino acids tested in the rat, any significant difference is observed in growth after the animal has been treated with L-Aspartic acid or L-arginine both in the brain as a whole and in the vesicles. This is probably due to the amount, already high, of these two amino acids found in the brain and to their metabolism.
T IT2011/000411
47
ESEMPIO 4: Study on the effects of the treatment with D-Aspartic acid L- Aspartic Acid, L-Arginine, with an association consisting in D-Aspartic acid and L-Aspartic acid, and an association consisting in D-Aspartic Acid and L -arginine on the health of rats
In order to exclude possible damage to the health of rats following the treatment with amino acids or associations thereof as above reported, after each rat had completed the cycle of exercises for learning and memory with the Water-Maze system, the rat was weighed and then decapitated by guillotine. Blood was collected as well as the serum from the blood. Then different types of clinical investigations were carried out on the blood and serum with the aim to verify if a damage in the tissues occurs. Analyses carried out were as follows: complete blood count (with the instrumewnt: HBxL80, HORIBA Medical, 34184 Montpellier, France), glucose, urea, ammonia, cholesterol, triglycerides, creatinine, uric acid, elec- trolytes: sodium, potassium, calcium, magnesium, iron, and copper. Then the following enzymes: transaminase, alkaline phosphatase, cholineste- rase and lactate dehydrogenase (using the instrument: LaB Taurus Instrument Laboratory SpA, Viale Monza 338, 20128 Milan), d) the following hormones: testosterone, T3, T4, (using the instrument: UnicellTM Dx1800, with Beckman Counter, Inc., 2505 Kraemer Blvd, Brea, CA 92821 Germany), and plasma protein electrophoresis (performed with the instrument: INTERLAB G26, Interlab Ltd., 00155 Rome). The result obtained from this study indicated that there was no significant variation in the values of the clinical analysis among the experimental groups and control group about each type of clinical investigation mentioned above (one-way ANOVA ") nor differences in their body weight.
In conclusion, the treatment with all compounds used for testing the rats have not any negative effect on the health of the animal.
EXAMPLE 5: Study on the effects of an association consisting of D- Aspartic acid and L-Arginine to improve memory in patients with dementia senile and Alzheimer's disease.
Based on the results obtained in rats about the improving of learn- ing and memory with the use of the compound consisting of D-Aspartic acid and L-Arginine, we were encouraged to test the same compound to increase the cognitive activities and memory in elder persons suffering from dementia senile in general and in particular suffering from Alzheimer's disease. For this purpose we conducted a pilot study of 6 elder pa- tients, three men and three women aged between 75 and 82 years, diagnosed as suffering from dementia senile with a dominant component of Alzheimer's disease.
Each patient was given a daily dose consisting of 2.5 g of D- Aspartic acid, 1.5 g of L-arginine. The mixture of the two amino acids was added 1.1 g of sodium bicarbonate in order to dissolve D-Aspartic acid and L-arginine in water. The patient was given to drink a solution made as above dissolved in half a glass of spring water or juice, preferably with food (lunch or after dinner). The treatment lasted for 30 consecutive days. After this time, for each patient the cognitive activities and memory, before and after treatment, have been assessed. The improvement or restoration of memory was evaluated using the following clinical parameters: Amnesia, Apraxia, Agnosia, Anomy, disorientation in time and space, agraphia, mood changes, language problems and loss of initiatives.
The results obtained in this study are showed in Table 13. As can be seen in said table, in all 6 patients who underwent the study, recovery of cognitive activities and memory occurs (Table 13). In fact, as can be seen in said table, the percentage of recovery of each parameter for the evaluation of the memory is large enough that each patient has recovered overall around 60-70% of the lost memory.
Table 13: Effect of an association of D-Aspartic acid and L-Arginine on cognitive activities and memory in dementia senile with a tendency to Alzheimer's
Recovery of cognitive activities and memory assessed by each symptom
Amnesia Apraxia Agnosia Anomy Disorientation Agraphy Mood Language Loss of
In time and space changes problems initiative
% of recovery of cognitive activities and memory
Female of 82 years 60-70 60-75 55-70 70-82 70-80 50 60-70 70-82 60-70
Female of 80 years 55-65 65-75 60-80 64-74 55-65 65-75 60-74 65-75 65-75
Female of 75 years 60-70 65-75 65-75 55-65 65-75 50-60 60-70 65-70 55-70
Male of 81 years 65-75 65-75 60-70 60-70 75-80 65-75 65-75 55-75 60-70
Male of 79 years 45-55 50-60 55-65 65-75 65-75 65-75 70-80 75-85 45-60
Male of 75 years 75-80 60-70 60-70 55-65 45-55 40-50 40-50 65-75 45-55
Each patient took a daily dose consisting of 2.5 g of D-Aspartic acid and 1.5 g of L-Arginine and fed for 30 days. The assessment of recovery of cognitive activities and memory has been expressed in terms of arbitrary evaluating before and after treatment, giving a value of 100% and cognitive activities and memory of people without dementia and of the same age group.
GENERAL CONCLUSIONS
In this study has been evaluated the possibility of using a mixture of D-Aspartic acid and L-Arginine acid by appropriate molecular ratios for the improvement of cognitive activities and memory in patients with dementia senile and Alzheimer's. The first study was carried out on different experimental groups of rats and then on a group of patients with dementia.
Rats were subjected to oral treatment of some amino acids alone and in association with each other. After a period of 30 days of treatment, the rats were tested by the Water-Maze Learning System, universally rec- ognized as a method suitable for this purpose. This study showed that, among the various combinations of amino acids tested, the mixture consisting of 20 mM D-aspartate acid and 10 mM L-arginine was found to be the most effective for the improvement of memory in rodents. In addition, the mixture consisting of 20 mM D-Aspartic acid and 20 mM L-arginine has efficiently responded for increasing memory.
It is also important to report that treatment with D-Aspartic acid alone or L-arginine alone, or a combination of D-Aspartic acid and L- Aspartic acid also improve learning and memory in rats, but their activity is only 1/ 5 of that induced by the association of D-Aspartic acid and L- arginine.
The human study consisted in giving a drinking dose per day including 2.5 g of D-Aspartic acid and 1.5 g of L-arginine dissolved in 1/2 glass of water for 30 consecutive days to a group of elder persons suffering from dementia senile with tendency to the Alzheimer's disease. The result showed that in all patients there was a recovery of 60-70% of memory.
Bibliography
Shankar G.M. et al., (2008). Amyloid -beta dimer isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nature Medicine 14: 837-842.
Davies P. et al., (1976) Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet
Onder G, Zanetti O, Giacobini E, Frisoni GB, Bartorelli L, Carbone G, Lambertucci P, Silveri MC, Bernabei R., (2005). Reality orientation therapy combined with cholinesterase inhibitors in Alzheimer's disease: randomized controlled trial, Br J Psychiatry. 187: 450-455.
Cochrane Birks J, Grimley Evans J. (2009). "Ginkgo biloba for cognitive impairment and dementia". Cochrane Database Syst Rev
Haugabook. S.J. et et al., (2001) Reduction of A beta accumulation in the Tg2576 animal model of Alzheimer's disease after oral administra- tion of the phophatidyl-inositol kinase inhibitor. FASEB J. 15, 16-18. Janus, C. et al., (2000) A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature, 408, 979-982.
D'Aniello, A., Giuditta, A. (1977) Identification of D-aspartic acid in the brain of Octopus vulgaris. J. Neurochem. 29, 1053-1057
D'Aniello, A. (2007) D-Aspartic acid: An endogenous amino acid with an important neuroendocrine role. Brain Research Reviews 53, 215-234. Hashimoto, A., Nishikawa, T., Oka, T., Hayashi, T., Takahashi, K. (1993) Widespread distribution of free D-aspartate in rat periphery.
FEBS Lett. 331 , 4-8
. Dunlop, D. S,, Neidle, A., McHale, D., Dunlop, D. M., Lajtha, A. (1986) The presence of free D-aspartic acid in rodents and man. Bio- chem. Bioph. Res. Co. 142, 27-. Neidle, A., Dunlop, D. S. (1990) Developmental changes of free D- aspartic acid in the chicken embryo and in the neonatal rat. Life. Sci.
46, 1517-152232
. Fisher, G. H., D'Aniello, A., Vetere, A., Padula, L, Cusano, G. P.,
Man, E. H. (1991) Free D-aspartate and D-alanine in normal and Alzheimer's brain. Brain. Res. Bull. 26, 983-985
15. Hashimoto, A., Kumashiro, S., Nishikawa, T., Oka, T., Takahashi, K., Mito, T., Takashima, S., Doi, N., Mizutani, Y., Yamazaki, T. (1993) Embryonic development and postnatal changes in free D-aspartate and
D-serine in the human prefrontal cortex. J. Neurochem. 61 , 348-351
16. D'Aniello, A., Di Cosmo, A., Di Cristo, C, Annunziato, L, Petrucelli, L, Fisher, G. H. (1996) Involvement of D-aspartic acid in the synthesis of testosterone in rat testes. Life Sci. 59, 97-104
17. D'Aniello, A., Di Fiore, M. M., Fisher, G. H., Milone, A., Seleni, A., D'Aniello, S., Perna, A. F., Ingrosso, D. (2000) Occurrence of D-aspartic acid and N-methyl-D-aspartic acid in rat neuroendocrine tissues and their role in the modulation of luteinizing hormone and growth hormone release. FASEB J. 14, 699-714
18. D'Aniello, A., Di Fiore, M. M., D'Aniello, G., Colin, F. E., Lewis, G., Setchell, B. P. (1998) Secretion of D-aspartic acid by the rat testis and its role in endocrinology of the testis and spermatogenesis. FEBS Lett 436, 23-27
19Nagata, Y., Homma, H., Lee, J. A., Imai, K. (1999) D-Aspartate stimula- tion of testosterone synthesis in rat Leydig cells. FEBS Lett. 444, 160-
164
20. Pampillo, M., Scimonelli, T., Bottino, M. C, Duvilanski, B. H., Retto- ri, V., Seilicovich, A., Lasaga, M. (2002) The effect of D-aspartate on luteinizing hormone-releasing hormone, a-melanocyte-stimulating hor- mone, GABA and dopamine release. Neuroreport A3, 2341-2344
21. Ishida, A. T., Gordon, G. (1981 ) D-aspartate potentiates the effects of L-glutamate on horizontal cells in goldfish retina. Proc. Natl. Acad. Sci. USA 78, 5890-5894
22. D'Aniello, S., Spinelli, P., Ferrandino, G., Peterson, K., Tsesarskaja, M., Fisher, G. H, D'Aniello, A. (2005) Cephalopod vision involves dicar- boxylic amino acids: D-aspartate, L-aspartate and L-glutamate. Bio- chem. J. 386, 331-340
23. Errico, F., Nistico, R., Napoletano, F., Mazzola, C, Astone, D., Pi- sapia, T., Giustizieri, M., D'Aniello, A., Mercuri, N. B., Usiello, A. (2010) Increased D-aspartate brain content rescues hippocampal age-related synaptic plasticity deterioration of mice. Neurobiol Aging. In Press 24. Topo, E., Soricelli, A., Di Maio. A., D'Aniello. E., Di Fiore, M. M., D'Aniello, A. (2010) Evidence for the involvement of D-Aspartic acid in learning and memory of rat. Amino Acids 38, 1561-1569
25. Fisher, G.H, D'Aniello, A., Vetere, A. Padula, L. Cusano G.S., and Man, E.H. (1991). Free D-aspartate and D-alanine in normal and Alz- heimer brain. Brain Res. Bull. 26, 983-985.
26. D'Aniello, A., Lee, J.M. Petrucelli L, and Di Fiore, M.M. (1998).
Regional decrease of free D-aspartate levels in Alzheimer's disease. Neuroscience Letters 250, 131-134.
27. D'Aniello, S., Spinelli, P., Ferrandino, G., Peterson, K., Tsesarskaja, M., Fisher, G. H, D'Aniello, A. (2005) Cephalopod vision involves dicar- boxylic amino acids: D-aspartate, L-aspartate and L-glutamate. Bio- chem. J. 386, 331-340
28 D'Aniello A., G.H. Fisher, N. Migliaccio, G. Cammina, E. D'Aniello and P. Spinelli. Amino acids and transaminase activity in ventricular CSF and in brain of normal and Alzheimer patients. Neurosci Letters.
388, 49-53, 2005.
29 Morris R, (1984) Developments of a water-maze procedure for studying spatial learning in the rat. J Neurosci Methods 11 : 47-60).
30. Shibata, K., Watanabe, T., Yoshikawa, H., Abe, K., Takahashi, S., Kera, Y., Yamada, R. H., (2003) Purification and characterization of aspartate racemase from the bivalve mollusk Scapharca broughtonii. Comp. Biochem. Physiol. B, 134, 307-314.
31. Foster, A. C, Fagg, G. E. (1987) Comparison of L-[3H]glutamate, D- [3H]aspartate, DL-[3H]AP5 and [3H]NMDA receptors in crude postsynap- tic densities from rat brain. Eur. J. Pharmacol. 133, 291-300
Claims
1. A combination comprising or consisting of D-Aspartic acid and L- Arginine and/or L-Aspartic acid or their salts for simultaneous, separate or sequential use in the treatment for restoring and/or improving of cognitive activities and memory for short and long period.
2. A pharmaceutical composition comprising or consisting of D- Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof as active ingredients in combination with one or more excipients and/or adjuvants pharmaceutically acceptable for use in the treatment for restoration and/or improvement of cognitive activities and memory for short and long period.
3. Pharmaceutical combination or composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to any claims 1-2, in patients with dementia such as dementia senile and Alzheimer's disease.
4. Pharmaceutical combination or composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to any claims 1-3, where the percentage of D- Aspartic acid or L-arginine or L-Aspartic acid or salts thereof varies from 0.1% to 99.9% compared to the total of such D-aspartic acid and L- arginine or said D-Aspartic acid and L-Aspartic acid or salts thereof.
5. Pharmaceutical combination or composition comprising or consisting of D-Aspartic acid and L-Arginine and / or L-Aspartic acid or salts thereof for use according to any claims 1-4, wherein said pharmaceutical combination or composition is administered in one or multiple daily doses, each dose comprising from 0.1 g to 10 g of D-Aspartic acid, 0.1 g to 10 g of L-Arginine and/or 0.1 g to 10 g L-Aspartic acid or salts thereof.
6. Pharmaceutical combination or composition comprising or consisting of D-Aspartic acid and L-Arginine and / or L-Aspartic acid or salts thereof for use according to any claims 1-5, wherein said combination or pharmaceutical composition further includes one or more basic or acidic substances in quantities suitable to bring pH to neutrality.
7. Pharmaceutical combination or composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to any one of claims 1-6, wherein said salts of D- Aspartic acid or L-Aspartic acid are selected from the group consisting of salts of Sodium, Potassium, Calcium, Magnesium, Zinc, Selenium, Copper, Manganese, Iodine.
8. Pharmaceutical combination or composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to any claims 1-7, wherein said pharmaceutical combination or composition further includes at least one amino acid chosen in the group consisting of acid D- or L-glutamic acid, D- or L- asparagine, D- or L-glutamine, D- or L-serine, D- or L-alanine, D- or L- threonine, D - or L-histidine, D-arginine, D- or L-cysteine, D- or L-cystine, D- or L-valine, D- or L-methionine, D- or L-tyrosine, D- or L- phenylalanine, D- or L-isoleucine, D- or L-leucine, D -or L-tryptophan, D- or L-carnitine, propionyl L- or D-carnitine, D- or L-acetyl-carnitine, L-xarnitine fumarate, carnosine, melatonin, theanine or salts thereof.
9. Pharmaceutical combination or composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to any claims 1-8, wherein said pharmaceutical combination or composition further includes a ketone or a salt thereof.
10. Pharmaceutical combination or composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to any claims 1-9, wherein said pharmaceutical combination or composition further includes at least one vitamin chosen in the group consisting of water-soluble vitamins such as Vitamin B1 , Vitamin B2, Vitamin B3, Vitamin PP, Vitamin B5, Vitamin B6, Vitamin Y, Vitamin B8, Vitamin B9, Vitamin B12, Vitamin C and fat-soluble vitamins such as Vitamin A, Vitamin D, Vitamin E, Vitamin K.
11. Pharmaceutical combination or composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to any claims 1-10, wherein said pharmaceutical combination or composition further includes at least one antioxidant chosen in the group consisting of coenzyme Q-10, ascorbic acid, folic acid, alpha-lipoic acid, glutathione, inosidol, tocopherols, tocotrienols, superoxide dismutase, lycopene, ellagic acid, melatonin.
12. Pharmaceutical combination or composition comprising or consisting of D-Aspartic acid and L-Arginine and/or L-Aspartic acid or salts thereof for use according to any claims 1-11 , wherein said pharmaceutical combination or composition further includes at least one ion metal chosen in the group consisting of magnesium, zinc, selenium, sodium, potassium, calcium, in the form of chlorides, sulphates, fluorides, or in the form of metal oxides.
13. A combination comprising or consisting of L-Aspartic acid and L-arginine or salts thereof for simultaneous, separate or sequential use for treatment for restoring and/or improving cognitive activities and memory in short and long period.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT000679A ITRM20100679A1 (en) | 2010-12-21 | 2010-12-21 | D-ASPARTIC ACID, L-ASPARTIC ACID, THEIR SALTS OR THEIR COMBINATIONS FOR THE RESTORATION OF THE COGNITIVE ACTIVITY AND OF THE MEMORY IN THE ALZHEIMER'S DISEASES AND IN OTHER SENILE DEEDS. |
PCT/IT2011/000411 WO2012085954A1 (en) | 2010-12-21 | 2011-12-21 | Combination comprising d-apartic acid and l-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile and alzheimer's disease |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2654743A1 true EP2654743A1 (en) | 2013-10-30 |
Family
ID=43737312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP11820851.1A Withdrawn EP2654743A1 (en) | 2010-12-21 | 2011-12-21 | Combination comprising d-apartic acid and l-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile and alzheimer's disease |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP2654743A1 (en) |
IT (1) | ITRM20100679A1 (en) |
WO (1) | WO2012085954A1 (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ITUB20153895A1 (en) * | 2015-09-25 | 2017-03-25 | Pasquale Gualdiero | ASSOCIATION OF CURCUMINA, ARGININA AND VITAMIN D |
JP6935994B2 (en) * | 2016-08-19 | 2021-09-15 | 株式会社明治 | Composition for promoting ketone body production |
IT201700068608A1 (en) * | 2017-06-20 | 2018-12-20 | Neilos S R L | Composition for treatment or prevention of a neurodegenerative disease |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE20311240U1 (en) * | 2003-07-21 | 2003-09-25 | Sportmedizin Team Vertriebs Gm | Composition for promoting mental power, comprises combination of L-leucine, L-valine, L-isoleucine, L-arginine, L-aspartic acid, choline and phenylalanine |
AU2004279298B2 (en) * | 2003-09-29 | 2009-01-29 | Palmetto Pharmaceuticals, Llc | Sustained release L-arginine formulations and methods of manufacture and use |
JP2006069958A (en) * | 2004-09-02 | 2006-03-16 | Bio Igaku Kenkyusho Kk | Age resistor |
EP2317994A4 (en) * | 2008-07-23 | 2012-09-12 | Massachusetts Inst Technology | Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival |
-
2010
- 2010-12-21 IT IT000679A patent/ITRM20100679A1/en unknown
-
2011
- 2011-12-21 EP EP11820851.1A patent/EP2654743A1/en not_active Withdrawn
- 2011-12-21 WO PCT/IT2011/000411 patent/WO2012085954A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
See references of WO2012085954A1 * |
Also Published As
Publication number | Publication date |
---|---|
ITRM20100679A1 (en) | 2012-06-22 |
WO2012085954A1 (en) | 2012-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Errico et al. | New insights on the role of free D-aspartate in the mammalian brain | |
Froestl et al. | SGS742: the first GABAB receptor antagonist in clinical trials | |
US20090004291A1 (en) | Compositions and methods for treating alzheimer's disease and dementia | |
CA2766282C (en) | Inhibitors of carnitin-palmitoyl-transferase-1 for the treatment and prevention of disorders caused by delipidation of neural tissue | |
Hagmeyer et al. | Prospects of zinc supplementation in autism spectrum disorders and Shankopathies such as Phelan McDermid Syndrome | |
WO2015057662A1 (en) | Compositions and methods for improving cognitive function | |
US20210251929A1 (en) | Anti-rds compounds and method of manufacture and administration thereof to induce dopamine homeostasis | |
KR20110127263A (en) | Compositions and methods for prophylaxis and treatment of addictions | |
EP2654743A1 (en) | Combination comprising d-apartic acid and l-arginine or salts thereof for the improvement of cognitive activities and memory in dementia such as dementia senile and alzheimer's disease | |
JP4421832B2 (en) | Memory accelerator | |
Delwing et al. | α-Tocopherol and ascorbic acid prevent memory deficits provoked by chronic hyperprolinemia in rats | |
EP3461479B1 (en) | Nutraceutical and pharmaceutical compositions, and uses thereof for preserving cognitive functions | |
EP3512530B1 (en) | Oral pyrophosphate for use in reducing tissue calcification | |
Hashimoto | The NMDA receptor hypofunction hypothesis for schizophrenia and glycine modulatory sites on the NMDA receptors as potential therapeutic drugs | |
JP5575662B2 (en) | Compositions and methods for treating neurodegenerative diseases | |
JPWO2018190146A1 (en) | Composition for treating and / or preventing Alzheimer's disease | |
JP5849368B2 (en) | Novel nutritional food composition containing thymol and / or p-cymene or plant extract for cognitive ability | |
WO2006125810A2 (en) | Composition for slowing down the development of alzheimer's disease | |
WO2018057514A1 (en) | Compositions for restoring gene expression in neuropsychiatric or neurodegenerative disorders | |
US9851354B2 (en) | Methods of treating fragile X syndrome and related disorders | |
JP7338828B2 (en) | Composition for improving cognitive function | |
KR102120376B1 (en) | Composition for preventing and/or treating a degenerative brain disease comprising as an active ingredient an extract of Cimicifuga dahurica, a fraction thereof, or a compound derived from Cimicifuga dahurica | |
EP0073173A1 (en) | Products extracted from invertebrate sea-animals, their preparation and their uses in dietetics,pharmaceutics and cosmetology | |
WO2010096539A1 (en) | Methods for treating lipomas and liposarcomas | |
Hamazaki et al. | Fatty acids and lipids: New findings |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20130618 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150701 |